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Abstract
Purpose: To evaluate the clinical impact of the Varian Exact Couch on dose and volume
coverage to targets and critical structures and tumor control probability (TCP) for 6-MV
IMRT and Arc Therapy.
Methods: Five clinical prostate patients were planned with both, 6-MV 8-field IMRT and 6MV 2-field RapidArc using the Eclipse treatment planning system (TPS). These plans
neglected treatment couch attenuation, as is standard clinical practice. Dose distributions
were then recalculated in Eclipse with the inclusion of the Varian Exact Couch (imaging
couch top) and the rails in varying configurations. The changes in dose and coverage were
evaluated using the DVHs from each plan iteration. We used a tumor control probability
(TCP) model to calculate losses in tumor control resulting from not accounting for the couch
top and rails. We also verified dose measurements in a phantom.
Results: Failure to account for the treatment couch and rails resulted in clinically
unacceptable dose and volume coverage losses to the target for both IMRT and RapidArc.
The couch caused average dose losses (relative to plans that ignored the couch) to the
prostate of 4.2% and 2.0% for IMRT with the rails out and in, respectively, and 3.2% and
2.9% for RapidArc with the rails out and in, respectively. On average, the percentage of the
target covered by the prescribed dose dropped to 35% and 84% for IMRT (rails out and in,
respectively) and to 18% and 17% for RapidArc (rails out and in, respectively). The TCP
was also reduced by as much as 10.5% (6.3% on average). Dose and volume coverage
losses for IMRT plans were primarily due to the rails, while the imaging couch top
contributed most to losses for RapidArc. Both the couch top and rails contribute to dose and
iv

coverage losses that can render plans clinically unacceptable. A follow-up study we
performed found that the less attenuating unipanel mesh couch top available with the Varian
Exact couch does not cause a clinically impactful loss of dose or coverage for IMRT but still
causes an unacceptable loss for RapidArc.
Conclusions: Both the imaging couch top and rails contribute to dose and coverage loss to a
degree that, if included, would prevent the plan from meeting clinical planning criteria.
Therefore, the imaging and mesh couch tops and rails should be accounted for in Arc
Therapy and the imaging couch and rails only in IMRT treatment planning.

v

Table of Contents
TABLE OF CONTENTS ....................................................................................................... VI
List of Figures ..................................................................................................................... ix
List of Tables...................................................................................................................... xv
List of Equations ............................................................................................................... xix
CHAPTER 1 INTRODUCTION ...............................................................................................1
1.1

Statement of Problem ................................................................................................ 1

1.2 Hypothesis and Specific Aims ....................................................................................... 9
CHAPTER 2 MATERIALS AND METHODS ......................................................................11
2.1 Relative Attenuation Measurements ............................................................................ 11
2.2 Varian Eclipse Treatment Planning System ................................................................. 12
2.2.1 IMRT Planning ...................................................................................................... 12
2.2.2

Varian RapidArc Planning .............................................................................. 15

2.2.3 Varian Exact Couch .............................................................................................. 18
2.3 Point Dose Evaluation .................................................................................................. 19
2.3.1 Plan Verification: IMRT QA ................................................................................. 19
2.4 DVH Analysis .............................................................................................................. 22
2.4.1 Dose ....................................................................................................................... 22
2.4.2 Relative volume coverage...................................................................................... 23
2.5 Tumor Control Probability (TCP) ................................................................................ 23
2.5.1 Niemierko and Goitein TCP Model ....................................................................... 23
CHAPTER 3 RESULTS ..........................................................................................................26
vi

3.1 Relative Attenuation Versus Gantry Angle.................................................................. 26
3.2 IMRT and RapidArc Plans ........................................................................................... 28
3.2.1 IMRT DVH’s ......................................................................................................... 28
3.2.2 IMRT MU’s ........................................................................................................... 32
3.2.3 IMRT Sample Plans ............................................................................................... 35
3.2.4 IMRT Sample Plan Subtractions ........................................................................... 38
3.2.5 RapidArc DVH’s ................................................................................................... 40
3.2.6 RapidArc MU’s ..................................................................................................... 44
3.2.7 RapidArc Sample Plans ......................................................................................... 46
3.2.8 RapidArc Sample Plan Subtractions ..................................................................... 48
3.3 Dosimetric Accuracy Evaluation ................................................................................. 51
3.3.1 Absolute Point Dose Analysis: TPS Couch Model Validation .............................. 51
3.3.2 Absolute Point Dose Analysis: Clinical QA Experience ....................................... 53
3.4

DVH Analysis: IMRT ............................................................................................. 55

3.4.1 Volume Coverage to Prostate and PTV: IMRT ..................................................... 55
3.4.2

Dose Loss to Prostate and PTV: IMRT ........................................................... 57

3.4.3 Critical Structures: IMRT ..................................................................................... 59
3.5 Tumor Control Probability: IMRT ............................................................................... 61
3.5.1 TCP Results: IMRT ............................................................................................... 61
3.6 DVH Analysis: RapidArc ............................................................................................ 62
3.6.1 Volume Coverage to Prostate and PTV: RapidArc ............................................... 62
3.6.2 Dose Loss to Prostate and PTV: RapidArc ........................................................... 64
3.6.3 Critical Structures: RapidArc ............................................................................... 66
vii

3.7 Tumor Control Probability: RapidArc ......................................................................... 68
3.7.1 TCP Results: RapidArc ......................................................................................... 68
CHAPTER 4 DISCUSSION....................................................................................................70
4.1

General Discussion ................................................................................................. 70

4.1.1 Specific Aim 1 ........................................................................................................ 70
4.1.2 Specific Aim 2 ........................................................................................................ 73
4.1.3 Specific Aim 3 ........................................................................................................ 75
4.1.4 Follow-Up Study: Mesh Couch Top ...................................................................... 80
CHAPTER 5 CONCLUSIONS ...............................................................................................84
5.2

Future Work ............................................................................................................ 86

CHAPTER 6 APPENDIX .......................................................................................................87
6.1 IMRT Plans .................................................................................................................. 87
6.1.1 IMRT DVH ............................................................................................................ 87
6.1.2 IMRT Isodose Comparisons .................................................................................. 89
6.1.3 IMRT Plan Subtractions ........................................................................................ 93
6.2 RapidArc Plans ............................................................................................................ 98
6.2.1 RapidArc DVH ...................................................................................................... 98
6.2.2 RapidArc Isodsose Comparisons ........................................................................ 101
6.2.3 RapidArc Plan Subtractions ................................................................................ 105
CHAPTER 7 BIBLIOGRAPHY ...........................................................................................110
CHAPTER 8 VITA................................................................................................................113

viii

List of Figures
Figure 2-1. MDACC clinical 8-field IMRT beam arrangement. ......................................... 13
Figure 2-2. 8-Field Beam Arrangement for IMRT with Imaging Couch Top and Rails.
Rails Out (left panel), Rails In (right panel). ......................................................................... 15
Figure 2-3. Sample 2-field RapidArc beam arrangement ................................................... 16
Figure 2-4. 2-arc beam arrangement for RapidArc with the couch top and rails. Left panel
shows rails out plan and right panel shows rails in plan........................................................ 17
Figure 2-5. Varian Exact imaging couch top and support rails ........................................... 18
Figure 2-6. Movable support rails on Varian Exact Couch ................................................. 18
Figure 2-7. Sample hybrid plan for clinical scenario RapidArc plan .................................. 20
Figure 2-8. Sample hybrid plan for RapidArc with imaging couch top and rails................ 20
Figure 3-1. Relative attenuation of Varian Exact couch tops and rails ................................ 26
Figure 3-2. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 1 showing structures as a function of relative volume and absolute
dose. The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 29
Figure 3-3. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 2 showing structures as a function of relative volume and absolute
dose. The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 30
Figure 3-4. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 3 showing structures as a function of relative volume and absolute
dose. The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 30
Figure 3-5. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 4 showing structures as a function of relative volume and absolute
dose. The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 31
Figure 3-6 DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch
Only) for patient 5 showing structures as a function of relative volume and absolute dose.
ix

The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 31
Figure 3-7. TPS optimized MU’s for each gantry angle ssed for IMRT plans.................... 32
Figure 3-8. Clinical scenario IMRT plan (left panel) and plan with rails out (right panel) for
patient 3 with prostate shown in blue colorwash ................................................................... 36
Figure 3-9. Clinical scenario IMRT plan (left panel) and plan with rails in (right panel) for
patient 3 with prostate shown in blue colorwash ................................................................... 37
Figure 3-10. Clinical scenario IMRT plan (left panel) and plan with imaging couch only
(right panel) for patient 3 with prostate shown in blue colorwash ........................................ 37
Figure 3-11. Clinical scenario IMRT plan subtracted from rails out plan for patient 3 with
prostate shown in blue colorwash .......................................................................................... 38
Figure 3-12. Clinical scenario IMRT plan subtracted from rails in plan for patient 3 with
prostate shown in blue colorwash .......................................................................................... 39
Figure 3-13. Clinical scenario IMRT plan subtracted from imaging couch top only plan for
patient 3 with prostate shown in blue colorwash ................................................................... 40
Figure 3-14. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 1 structures as a function of relative volume and absolute dose. The
PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively. ........................................................................................................................... 41
Figure 3-15. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 2 structures as a function of relative volume and absolute dose. The
PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively. ........................................................................................................................... 42
Figure 3-16. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 3 structures as a function of relative volume and absolute dose. The
PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively. ........................................................................................................................... 42
Figure 3-17. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 4 structures as a function of relative volume and absolute dose. The

x

PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively. ........................................................................................................................... 43
Figure 3-18. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging
Couch Only) for patient 5 structures as a function of relative volume and absolute dose. The
PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively. ........................................................................................................................... 43
Figure 3-19. Clinical scenario RapidArc plan (left panel) and rails out plan (right panel) for
patient 3 with prostate shown in blue colorwash ................................................................... 46
Figure 3-20. Clinical scenario RapidArc plan (left panel) and rails in plan (right panel) for
patient 3 with prostate shown in blue colorwash ................................................................... 47
Figure 3-21. Clinical scenario RapidArc plan (left panel) and imaging couch only plan
(right panel) for patient 3 with prostate shown in blue colorwash ........................................ 48
Figure 3-22. Clinical scenario RapidArc plan subtracted from rails out plan for patient 3
with prostate shown in blue colorwash .................................................................................. 49
Figure 3-23. Clinical scenario RapidArc plan subtracted from rails in plan for patient 3
with prostate shown in blue colorwash .................................................................................. 50
Figure 3-24. Clinical scenario RapidArc plan subtracted from the imaging couch top only
plan for patient 3 with prostate shown in blue colorwash ..................................................... 51
Figure 4-1. Varian Exact Couch with mesh top insert ......................................................... 81
Figure 6-1. Relative volume vs absolute dose DVH for patient 1 (small prostate). The
PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 88
Figure 6-2. Relative volume vs absolute dose DVH for patient 3 (medium prostate). The
PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively ............................................................................................................................ 88
Figure 6-3. Relative volume vs absolute dose DVH for patient 4 (large Prostate). The PTV,
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively.... 89
Figure 6-4. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for
patient 1 (small prostate) with prostate shown in red colorwash........................................... 90

xi

Figure 6-5. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for
patient 1 (small prostate) with prostate shown in red colorwash........................................... 90
Figure 6-6. Clinical scenario IMRT plan (left panel) and imaging couch top only plan (right
panel) for patient 1 (small prostate) with prostate shown in red colorwash .......................... 91
Figure 6-7. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for
patient 3 (medium prostate) with prostate shown in blue colorwash .................................... 91
Figure 6-8. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for
patient 3 (medium prostate) with prostate shown in blue colorwash .................................... 91
Figure 6-9. Clinical scenario IMRT plan (left panel) and imaging couch top only plan (right
panel) for patient 3 (medium prostate) with prostate shown in blue colorwash.................... 92
Figure 6-10. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for
patient 4 (large prostate) with prostate shown in blue colorwash ......................................... 92
Figure 6-11. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for
patient 4 (large prostate) with prostate shown in blue colorwash ......................................... 92
Figure 6-12. Clinical scenario IMRT plan (left panel) and imaging couch top only (right
panel) for patient 4 (large prostate) with prostate shown in blue colorwash ......................... 93
Figure 6-13. Clinical scenario IMRT Plan subtracted from rails out plan for patient 1 (small
prostate) with prostate shown in blue colorwash ................................................................... 94
Figure 6-14. Clinical scenario IMRT Plan subtracted from rails in plan for patient 1 (small
prostate) with prostate shown in blue colorwash ................................................................... 94
Figure 6-15. Clinical scenario IMRT Plan subtracted from imaging couch top only plan for
patient 1 (small prostate) with prostate shown in blue colorwash ......................................... 95
Figure 6-16. Clinical scenario IMRT plan subtracted from rails out plan for patient 3
(medium prostate) with prostate shown in blue colorwash ................................................... 95
Figure 6-17. Clinical scenario IMRT plan subtracted from rails in plan for patient 3
(medium prostate) with prostate shown in blue colorwash ................................................... 96
Figure 6-18. Clinical scenario IMRT plan subtracted from imaging couch top only plan for
patient 3 (medium prostate) with prostate shown in blue colorwash .................................... 96
Figure 6-19. Clinical scenario IMRT plan subtracted from rails out plan for patient 4 (large
prostate) with prostate shown in blue colorwash ................................................................... 97
xii

Figure 6-20. Clinical scenario IMRT plan subtracted from rails in plan for patient 4 (large
prostate) with prostate shown in blue colorwash ................................................................... 97
Figure 6-21. Clinical scenario IMRT plan subtracted from imaging couch top only plan for
patient 4 (large prostate) with prostate shown in blue colorwash ......................................... 98
Figure 6-22. Relative volume vs absolute dose RapidArc DVH for patient 1 (small
prostate). The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and
yellow, respectively ............................................................................................................... 99
Figure 6-23. Relative volume vs absolute dose RapidArc DVH for patient 3 (medium
prostate). The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and
yellow, respectively ............................................................................................................. 100
Figure 6-24. Relative volume vs absolute dose RapidArc DVH for patient 4 (large
prostate). The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and
yellow, respectively ............................................................................................................. 100
Figure 6-25. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for
patient 1 (small prostate) with prostate shown in blue colorwash ....................................... 101
Figure 6-26. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for
patient 1 (small prostate) with prostate shown in blue colorwash ....................................... 102
Figure 6-27. Clinical scenario RapicPlan (left panel) and imaging couch top only (right
panel) for patient 1 (small prostate) with prostate shown in blue colorwash ...................... 102
Figure 6-28. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for
patient 3 (medium prostate) with prostate shown in blue colorwash .................................. 103
Figure 6-29. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for
patient 3 (medium prostate) with prostate shown in blue colorwash .................................. 103
Figure 6-30. Clinical scenario RapicPlan (left panel) and imaging couch top only plan (right
panel) for patient 3 (medium prostate) with prostate shown in blue colorwash.................. 103
Figure 6-31. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for
patient 4 (large prostate) with prostate shown in blue colorwash ....................................... 104
Figure 6-32. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for
patient 4 (large prostate) with prostate shown in blue colorwash ....................................... 104

xiii

Figure 6-33. Clinical scenario RapicPlan (left panel) and imaging couch top only plan (right
panel) for patient 4 (large prostate) with prostate shown in blue colorwash ....................... 105
Figure 6-34. Clinical scenario RapidArc Plan subtracted from rails out plan for patient 1
(small prostate) with prostate shown in blue colorwash ...................................................... 105
Figure 6-35. Clinical scenario RapidArc Plan subtracted from rails in plan for patient 1
(small prostate) with prostate shown in blue colorwash ...................................................... 106
Figure 6-36. Clinical scenario RapidArc Plan subtracted from imaging couch top only plan
for patient 1 (small prostate) with prostate shown in blue colorwash ................................. 106
Figure 6-37. Clinical scenario RapidArc plan subtracted from rails out plan for patient 3
(mean prostate) with prostate shown in blue colorwash ...................................................... 107
Figure 6-38. Clinical scenario RapidArc plan subtracted from rails in plan for patient 3
(mean prostate) with prostate shown in blue colorwash ...................................................... 107
Figure 6-39. Clinical scenario RapidArc plan subtracted from imaging couch top only plan
for patient 3 (mean prostate) with prostate shown in blue colorwash ................................. 108
Figure 6-40. Clinical scenario RapidArc plan subtracted from rails out plan for patient 4
(large prostate) with prostate shown in blue colorwash ...................................................... 108
Figure 6-41. Clinical scenario RapidArc plan subtracted from rails in plan for patient 4
(large prostate) with prostate shown in blue colorwash ...................................................... 109
Figure 6-42. Clinical scenario RapidArc plan subtracted from imaging couch top only plan
for patient 4 (large prostate) with prostate shown in blue colorwash .................................. 109

xiv

List of Tables
Table 2-1. MDACC clinical DVH planning constraints for external photon beam treatment
of the prostate. ....................................................................................................................... 13
Table 3-1. Relative attenuation of Varian Exact imaging and mesh top with rails. The pink
highlighting represents angles over which the couch top and rails intersected with the beam.
............................................................................................................................................... 27
Table 3-2. MU and normalization values for each plan iteration for patient 1 .................... 33
Table 3-3. MU and normalization values for each plan iteration for patient 2 .................... 34
Table 3-4. MU and normalization values for each plan iteration for patient 3. The numbers
in bold are the angles that differed in MU compared to the clinical scenario plan. .............. 34
Table 3-5. MU and normalization values for each plan iteration for patient 4 .................... 35
Table 3-6. MU and normalization values for each plan iteration for patient 5 .................... 35
Table 3-7. The TPS optimized MU’s for the two arc fields for RapidArc plans .................. 44
Table 3-8. MUs and normalization values for each plan iteration for patient 1 .................. 44
Table 3-9. MUs and normalization values for each plan iteration for patient 2 .................. 45
Table 3-10. MUs and normalization values for each plan iteration for patient 3 ................ 45
Table 3-11. MUs and normalization values for each plan iteration for patient 4 ................ 45
Table 3-12. MUs and normalization values for each plan iteration for patient 5 ................ 45
Table 3-13. TPS-calculated dose for IMRT plans including the couch and rails compared to
the measured dose for specified plan delivery. ...................................................................... 52
Table 3-14. TPS-calculated dose for RapidArc plans including the couch and rails
compared to the actual measured dose for specified plan delivery. ...................................... 52
Table 3-15. TPS-calculated dose for IMRT plans not accounting for the couch and rails
(clinical scenario) compared to the measured dose with the couch and rails ........................ 53
Table 3-16. TPS-calculated dose for RapidArc plans not accounting for the couch and rails
(clinical scenario) compared to the measured dose with the couch and rails ........................ 54
3-17. Average percentage differences between measured point doses and TPS-calculated
point doses for hybrid plans that included the couch and rails and plans that did not include
these structures per normal IMRT QA protocol. ................................................................... 55

xv

Table 3-18. Percent coverage of target structures for clinically optimized IMRT plans for
each patient at prescription dose of 76Gy.............................................................................. 55
Table 3-19. Percent coverage of target structures for rails out IMRT plans at prescription
dose of 76Gy .......................................................................................................................... 56
Table 3-20. Percent coverage of target structures for rails in IMRT plans at prescription
dose of 76Gy .......................................................................................................................... 56
Table 3-21. Percent coverage of target structures for imaging couch top only IMRT plans at
prescription dose of 76Gy...................................................................................................... 56
Table 3-22. Average relative volume coverage at prescription dose of 76 Gy to prostate and
PTV target structures for IMRT Plans with varying rail configurations ............................... 56
Table 3-23. Minimum, maximum, and mean prescription dose loss between the clinical
scenario and rails out plans for all IMRT patients’ target structures ..................................... 57
Table 3-24. Minimum, maximum, and mean prescription dose loss between the clinical
scenario and rails in plans for all IMRT patients’ target structures ....................................... 58
Table 3-25. Minimum, maximum, and mean prescription dose loss between the clinical
scenario and imaging couch top only plans for all IMRT patients’ target structures ............ 58
Table 3-26. Average prescription dose loss between the clinical scenario and plans with
rails out, rails in, and imaging couch top only for IMRT ...................................................... 58
Table 3-27. Dose-volume data for each IMRT clinical scenario plan as a function of
clinical DVH dose-volume constraints .................................................................................. 59
Table 3-28. Dose-volume data for each IMRT rails out plan as a function of clinical DVH
dose-volume constraints ........................................................................................................ 59
Table 3-29. Dose-volume data for each IMRT rails in plan as a function of clinical DVH
dose-volume constraints ........................................................................................................ 60
Table 3-30. Dose-volume data for each IMRT imaging couch top only plan as a function
of clinical DVH dose-volume constraints.............................................................................. 60
Table 3-31. Averaged dose-volume data for all IMRT plan iterations as a function of
clinical DVH dose-volume constraints .................................................................................. 60
Table 3-32. IMRT TCP results for each patient’s clinical scenario, rails out, and rails in
plans ....................................................................................................................................... 61
xvi

Table 3-33. IMRT TCP results averaged over all patients .................................................. 61
Table 3-34. Percent prescription dose coverage of target structures for clinically optimized
RapidArc plans ...................................................................................................................... 62
Table 3-35. Percent prescription dose coverage of target structures for rails out RapidArc
plans ....................................................................................................................................... 63
Table 3-36. Percent prescription dose coverage of target structures for rails in RapidArc
plans ....................................................................................................................................... 63
Table 3-37. Percent prescription dose coverage of target structures for imaging couch top
only RapidArc plans .............................................................................................................. 63
Table 3-38. Average relative volume coverage at prescription dose of 76 Gy to prostate
and PTV target structures for RapidArc Plans with varying rail configurations ................... 63
Table 3-39. Minimum, maximum, and mean prescription dose loss between the clinical
scenario and rails out plans for RapidArc patients’ target structures .................................... 64
Table 3-40. Minimum, maximum, and mean prescription dose loss between the clinical
scenario and rails in plans for RapidArc patients’ target structures ...................................... 64
Table 3-41. Minimum, maximum, and mean prescription dose loss between the clinical
scenario and imaging couch top only plans for RapidArc patients’ target structures ........... 65
Table 3-42. Average prescription dose loss between the clinical scenario and plans with
rails out, rails in, and imaging couch top only for RapidArc patients’ target structures ....... 65
Table 3-43. Dose-volume data for each RapidArc clinical scenario plan as a function of
clinical DVH dose-volume constraints .................................................................................. 66
Table 3-44. Dose-volume data for each RapidArc rails out plan as a function of clinical
DVH dose-volume constraints ............................................................................................... 67
Table 3-45. Dose-volume data for each RapidArc rails in plan as a function of clinical
DVH dose-volume constraints ............................................................................................... 67
Table 3-46. Dose-volume data for each RapidArc imaging couch top only plan as a
function of clinical DVH dose-volume constraints ............................................................... 67
Table 3-47. Average dose-volume data for all plan iterations as a function of clinical DVH
dose-volume constraints ........................................................................................................ 68

xvii

3-48. RapidArc TCP results for each patient’s clinical scenario, rails out, and rails in plans
............................................................................................................................................... 69
3-49. RapidArc TCP results averaged over all patients ........................................................ 69
Table 4-1. Coverage of target structures at prescription dose for IMRT with mesh couch top
only ........................................................................................................................................ 81
Table 4-2. Average coverage of targets at prescription dose for IMRT plans comparing both
couch tops .............................................................................................................................. 82
Table 4-3. Average percentage of minimum, maximum, and mean prescription dose loss
from both couch tops ............................................................................................................. 82
Table 4-4. Coverage of target structures at prescription dose for RapidArc with mesh couch
top only .................................................................................................................................. 83
Table 4-5. Average coverage of targets at prescription dose for RapidArc plans for both
couch tops .............................................................................................................................. 83
Table 4-6. Average percentage of minimum, maximum, and mean prescription dose loss
from both couch tops ............................................................................................................. 83

xviii

List of Equations
Equation 2-1 Percent difference equation ............................................................................ 12
Equation 2-2. MDACC clinical IMRT QA dose factor equation....................................... 21
Equation 2-3. Percent difference equation .......................................................................... 22
Equation 2-4. Equation for relative volume ........................................................................ 23
Equation 2-5. Niemierko and Goitein TCP equation .......................................................... 24
Equation 2-6. Equivalent uniform dose (EUD) equation used in Niemierko and Goitein
TCP model ............................................................................................................................. 24

xix

Chapter 1 Introduction
1.1 Statement of Problem
The American Cancer Society estimates over 1.5 million new cases of cancer were
diagnosed in 2010 in the United States (1). Of those, approximately 78% will be treated with
radiation either alone or in conjunction with other therapies (2). Among the various types of
cancer, and of interest to this study, adenocarcinoma of the prostate is the most commonly
diagnosed cancer in men with an estimated 217,730 newly diagnosed cases and 32,050
deaths in the United States in 2010. The radiation therapy treatment options for men
diagnosed with prostate cancer are brachytherapy or external beam therapy with photons or
protons (1). The main objective of any therapeutic-option involving radiation is to
maximize tumor-control while minimizing toxicity to normal surrounding tissues and
structures. With that goal in mind, innovations in the field of diagnostic imaging have
enabled 3-D imaging of internal anatomy with excellent spatial resolution. These advances
provide images that contain information about scattering, absorption, and attenuation of
photon beams by the anatomical structures, which are essential calculation parameters in any
treatment planning system. Advances in imaging capabilities have also improved the
detection of microscopic disease. The improvement in malignancy-detection has also led to
an improvement in the ability to treat disease with an increasing ability to spare surrounding
normal tissues and structures.
Two of the forms of external beam radiation treatment available to prostate cancer
patients are intensity modulated radiation therapy (IMRT) and Arc Therapy. Both treatment
modalities have the ability to balance the need to provide high, conformal dose to diseased
1

target structures while sparing normal tissues surrounding the tumor. These modalities rely
on inverse treatment planning, where planning software calculates the optimal fluence to
achieve the input dose constraints. IMRT refers to a technique for delivering a nonuniform
fluence to a target from many gantry angles such that the composite dose is optimized to
meet input prescription dose. IMRT dose calculation algorithms achieve an optimal
distribution of dose within a target by varying the fluence of each incident treatment beam
by modulating smaller segments of each beam (3). This modulation can be accomplished
with the use of multileaf collimators (MLCs), small tungsten alloy collimating rods driven
by motors to block and shape the delivery fields (4). The delivery of IMRT can also vary
depending on how the intensity modulation is performed with the MLC’s: step-and-shoot
IMRT involves movement of the MLC’s to one-position per segment to achieve intensity
modulation while dynamic IMRT involves continuous MLC motion for each field (3).
IMRT treatments are delivered using a fixed number of gantry angles; for example, standard
clinical prostate cancer IMRT plans have an 8-field beam arrangement (at MD Anderson
Cancer Center [MDACC]). In such delivery modalities, the dose is modulated and delivered
only at specified gantry angles, and is not continuously modulated with gantry angle as is
the case for Arc Therapy.
Instead of the gantry being stationary while each treatment field is delivered, it is
possible to deliver dose continuously while the MLC modulates the beam fluence over
small, incremental gantry angles. Intensity modulated therapy delivered with the gantry
rotating, known as intensity modulated arc therapy (IMAT), was first proposed by Cedric
Yu in 1995 as an alternative for tomotherapy (5). IMAT involves dynamic beam-shaping by
the MLC as the gantry rotates. To deliver the desired modulated dose, several arcs with
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different MLC patterns and dose delivery may be necessary. Initially, this technique was
implemented using forward planning, while IMRT involves inverse planning, and involved
calculations of fields at fixed angles that were 5-10 degrees apart, making it more similar to
IMRT delivery instead the intended continous delivery (6). In 2007, Karl Otto developed a
technique he called volume modulated arc therapy (VMAT) that allowed for inverse
planning and dynamic MLC calculation for small gantry angle motions (7). This led to the
advent of several treatment planning and delivery platforms, of most interest to this study,
Varian RapidArc with the Eclipse treatment planning (Varian Medical Systems, Palo Alto,
CA).
With almost 80% of the cancer patient population receiving some form of radiation
therapy, there is a need for continual research and investigation into methods for ensuring
adequate and accurate radiation dose to treatment volumes and dose-sparing to critical
structures. While treatment prescription and critical structure tolerances vary from
institution to institution and even physician to physician, there are some treatment
commonalities such as the use of treatment couches for patient positioning. With few
exceptions (such as total skin irradiation), patients are positioned prone or supine on a
treatment couch for radiation therapy. The patient couch is meant to provide a means for
reproducible patient positioning. Patients can be further positioned with use of various
devices such as masks to hold the head and neck in a fixed position or cradles that hold the
body in fixed position, but these are patient- and treatment-specific devices that are separate
from the treatment couch.
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Given the necessity for the couch to be rigid enough to support large patients without
sagging, the construction material of the treatment couch has two important constraints: it
must be strong and durable enough to meet manufacturer’s sag tolerances and it should be
radio-transparent enough to not appreciably attenuate the therapy beam when radiation fields
intersect the couch. The couch tops are generally made of carbon fiber, which has a lowdensity, and are, therefore, considered to be radio translucent. Additionally, the Varian
Exact couch used in this study is supported by carbon fiber rails that allow the couch to
move forward and backward for correct patient positioning and can also be moved laterally
in and out. Due to the assumption of radio translucence, the effects of the couch and rails on
the treatment beam are not generally included in treatment planning or other dose
calculations even when the beam traverses the couch and rails during treatment. However,
studies investigating beam attenuation by treatment couches and rails have shown relatively
large amounts of beam attenuation at angles over which the beam transverses the couch and
rails.
In a study by McCormack et al in 2005, the magnitude of the attenuation by a Sinmed
Posisert treatment couch top over posterior oblique gantry angles was measured in a solid
water phantom by an isocentrically placed ion chamber. They found that for a 6-MV photon
beam of field size 10 cm x 5 cm, there was substantial attenuation by the couch top; 2% at
normal incidence between the couch and beam and reaching a maximum of 9% (8). A study
by Gerig et al in 2010, evaluated the attenuation properties of two different treatment
couches: the CIVCO and Medical Intelligence couches, using the same method as the
previously mentioned study. They found that each couch had different beam attenuation
properties and that the maximum beam attenuation was 7% (9). A study by Njeh et al in
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2009, repeated these measurements for a different couch top, the BrainLAB imaging couch,
and found a maximum attenuation of 8.3% at a 120 degree gangtry angle for a 6 MV
treatment beam (10). A study published by Mihaylov et al in 2010 within a few months of
the study by Njeh et al found a maximum attenuation of 8% by the BrainLab couch top for a
6 MV treatment beam (11). This helps to demonstrate that although the magnitude of
attenuation varies depending on the manufacturer and specific compostion of the couch top,
that there has been reproducibility of results in the literature when the same couches are
evaluated.
All of the aforementioned studies evaluated the relative attenuation on various treatment
couch tops, however, they did not evaluate the impact that the support rails have if traversed
by the beam. Because the support rails act to support the couch top and prevent sag when
substantial weight is placed upon it, it may be expected that the rails would attenuate more
than the couch top. Studies evaluating the degree of attenuation when both the treatment
couch top and rails are traversed found up to 17% attenuation for some posterior oblique
fields (12,13,14). The attenuation from the rail structures is much higher than from the
couch top alone compared to any study mentioned. However, as Mihaylov et al in 2008
noted, these couch rails can be moved to avoid the beam path for posterior oblique fields,
making its contribution to attenuation interesting but potentially not clinically revelant (11).
Nevertheless, clinical practice shows that the couch rails are often not moved during
treatment. In such cases, attenuation from the rails does have the potential to impact clinical
care. Moreover, while moving the rail to avoid the beams is feasible for IMRT treatments, it
is not feasible for Arc Therapy treatments that involve intersections with the couch and rails
since the delivery is continious. So while the attenuation that needs to be accounted for may
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be reduced to between 2% and 9% when the rails are moved out of the treatment beam for
IMRT, the attenuation of up to 17% by the couch top and rails is often not avoided in
clinical IMRT practice and cannot be avoided for Arc Therapy.
The problem inferred by the large attenuations observed in these studies is the
potential effect on patients treated with posterior fields. Since the treatment couch is not
normally accounted for in treatment planning, the dosimetric effect of the attenuation on
target and normal tissue structures cannot be anticipated. The attenuation through posterior
fields could cause a loss of dose and coverage of structures along the path. The result would
be, at the very least, the actual dose distribution not matching the plan with no clinical
consequence to treatment or, at most, an inadequate dose delivered to the target for tumorcontrol as assumed by the prescription dose. Despite the large attenuation demonstrated by
the couch top and rails in the literature, only one study to-date has evaluated what target
dose perturbation can result from the attenuation on patient cases (14). For the most part,
the limiting aspect in evaluating the target dose pertubation is incorporation of the couch top
and rails in a treatment planning system (TPS) to quantify the dose effect. TPS calculate
dose using information from 3-dimensional CT data sets of patient anatomy. When a patient
has a planning or simulation CT, they are positioned as they would be for actual treatment;
however, the couch top they are positioned on is not necessarily the same as the treatment
couch. The simulation couch can be of different dimensions or composition as the treatment
couch. Consequently, information about the treatment couch is not available from the
patient’s simulation scan and cannot be included in treatment planning. Furthermore, even if
the treatment couch and imaging couch are the same, the CT data of the imaging couch is
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removed from the plan before treatment planning so no couch-related effects are taken into
account.
There are techniques available to incorporate the treatment couch into the patient CT
image dataset, and thereby include this information in the treatment planning process. In
order to incorporate the treatment couch and/or rails in a treatment planning system, the
three studies to be discussed used a similar methodology. The first, a study published by
Myint et al in 2006, incorporated the couch top into a TPS by taking a CT image of the
Medtec therapy couch top, transferring the CT DICOM RT images to the TPS where dose
calculations were performed as normal for other structures (13). The next study published
by Mihaylov et al in 2008 imported the couch CT data set into a TPS by taking CT
simulation images of each of the couch top components, modifying the couch dimensions
and CT properties to match the manufacturer’s specifications in the TPS, and contouring the
couch components so the TPS could calculate dose through the couch top (11). The basic
methodology for incorporation of the couch top was the same for these first two studies;
however, the rails associated with the couch tops were not incorporated. Only one study
found in the literature attempted to include the rails in order to look at their dosimetric
impact. This study published by Prooijen et al in 2010, like the others, incorporated the
couch tops by importing CT images of those components. However, for the non-mobile
couch parts, including the rails one of the couches evaluated, the authors created ROI’s
within the TPS and assigned uniform density values consistent with the overall density of
the rails, failing to account for the heterogeneity of the rails (14).
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In the study by Myint et al, evaluating dosimetric impact of the couch using the
methodology mentioned previously, it was found that inclusion of the couch top into their
TPS reduced the dose error from 7.4% to less than 1.4% as determined via dose
measurements in a phantom with and without the couch top being taken into account (13).
Similarly, the study by Mihaylov et al found agreement with their TPS to within 1.7% when
the couch top was included. They further concluded that the couch top increases the skin
dose to a patient for posterior fields as determined by measuring PDD’s of beams passing
through the couch top (11). The most extensive study of dosimetric impact of the treatment
couch and rails was done by Prooijen et al in 2010. They found that their TPS agreed to
within 3% for calculated dose versus measured dose in a phantom when the couch top was
included in the TPS and within 2% for a single patient case (14). They went further by
evaluating the loss of dose and coverage to the PTV and CTV of five previous IMRT
clinical cases that involved posterior fields when the couch top and rails were included in the
dose calculations. This was done by preserving the beam angles and MU’s for the clinical
plan that was optimized without the presence of the couch and rails. They found a loss of
3% coverage to the PTV (as defined by the 95% isodose line), 1% for CTV coverage, and a
point dose reduction of 8+ 3% (14). However, the disease sites, prescriptions, and beam
arrangements used in these five cases were not divulged and cannot be compared to our
study.
Despite the demonstration of dosimetric impact of the couch top and/or rails by these
studies, a simplified way to include the couch top and rails in clinical patient plans has not,
to the author’s knowledge, been explored in the literature. Also, evaluation of the impact on
critical normal tissue structures has not been evaluated which is potentially important as
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treatment planning often involves using normal tissue constraints to create appropriate
treatment plans. The long term impact of ignoring the couch and rails in treatment planning
on tumor control probability (TCP) has also not been explored. Finally, no previous studies
have evaluated the impact of the treatment couch on Arc Therapy, although the paper by
Prooijen et al mentions this as an important future direction of research (14). This thesis
extends upon the work done by the various background studies, in that the clinical impact to
both target and critical structures is evaluated for both IMRT and Arc Therapy for both the
couch top and rails individually using Varian Eclipse treatment planning system (Varian
Medical Systems, Palo Alto, CA). This work uses Eclipse’s couch top and rail model after
first verifying its accuracy with measurements.
1.2 Hypothesis and Specific Aims
We hypothesized that the presence of the Varian Exact imaging couch top and rails
would not demonstrate a clinical impact for IMRT and Arc Therapy. A clinical impact was
defined to be a change that would cause a failure of the plan based on clinical planning
criteria used in our clinic: 98% coverage of prescription dose to the prostate, 95% to the
PTV, meeting of normal tissue DVH constraints, or a reduction in tumor control probability
(TCP). This was assessed by completion of the following three aims:
1. Measure the relative attenuation as a function of gantry angle for a 6-MV photon
beam to establish the dose attenuating properties of the Varian Exact imaging couch
top, mesh couch top, and rails.
2. Validate the Eclipse TPS couch model by evaluating absolute dose agreement
between the Eclipse TPS dose calculations and dose measured in IMRT QA phantom
9

for five prostate cancer patients planned with both 8-field IMRT and 2-arc RapidArc
plans.
3. Compare the DVH’s for each clinical (no couch) plan and subsequent plans that
include the treatment couch and rails to evaluate the dose and coverage loss to
targets and critical normal tissue structures and tumor control probability (TCP)
reduction.
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Chapter 2 Materials and Methods
2.1 Relative Attenuation Measurements
The relative attenuation of two Varian Exact couch inserts (imaging and mesh) and
the rails were measured for a 6-MV photon beam on a Varian Clinac® 2100C linear
accelerator (Varian Medical Systems, Palo Alto, CA). A PTW Farmer ion chamber (PTW,
Freiburg, Germany) was positioned isocentrically at a height of 10 cm above the couch
using the linear accelerator’s (linac’s) alignment lasers. Once aligned, a PMMA build-up
cap of 7.6 mm wall thickness (total thickness of 1.52 cm) thickness to maintain electronic
equilibrium for a 6-MV beam was placed over the ion chamber. A CNMC Model 206
electrometer (CNMC, Nashville, TN) was used to take the charge readings from the ion
chamber.
A 10x10 cm2 field size and machine output of 50 MU was used for all
measurements. An initial reading at 0, 90, and 270 degrees of gantry rotation was taken to
ensure proper alignment of the chamber’s active volume to linac isocenter. Specifically, the
chamber position was adjusted until these three angles produced readings that agreed within
0.1 nC. Two readings were then taken at each angle over a range of angles. These
measurements were made at small angle increments to ensure adequate sampling of
attenuation of the couch and rails. First, the imaging couch top was used and measurements
were taken with the rails in their outmost position. The measurements were then repeated
for the imaging couch top with the rails moved in their innermost position. Finally, the
couch top was replaced with the mesh couch top and the measurements repeated with the
rails out.
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Relative beam attenuation as a function of gantry angle was assessed using the
average of the two reading. The average of the reading taken at 0 degree gantry rotation was
assumed to be 0% attenuation as the beam does not pass through an attenuating structure
before encountering the ion chamber. The relative attenuation for all other gantry angles
was then calculated as a percent difference between the measured reading and the reading at
0 degrees gantry rotation.

Equation 2-1 Percent difference equation

Where M is ion chamber reading in nano Coulombs at a gantry angle x.
2.2 Varian Eclipse Treatment Planning System
2.2.1 IMRT Planning
Five prostate cancer patients with clinically contoured CT simulation images in the
Eclipse TPS database were chosen for inclusion in the study. All patients had intact
prostates and were planned with a prescription dose of 76 Gy: 2 Gy per fraction for 38
fractions. This is the standard fractionation at MDACC. All patients were planned with the
MDACC standard 8-beam field arrangement at gantry angles of 225, 260, 295, 330, 30, 65,
100, and 135 degrees with 6-MV photon beams as seen in Figure 2-1.
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Figure 2-1. MDACC clinical 8-field IMRT beam arrangement.

The collimator and couch rotation were set to 0 degrees for all plans. Clinically, the
prostate and PTV structures are contoured by the physician and have clinical dose and
coverage constraints assigned to them. A plan was considered to be clinically acceptable
when at least 98% of the prostate and 95% of the planning tumor volume (PTV) was
covered by the prescription dose and the following DVH dose constraints were met for the
critical normal tissue structures. The clinical DVH constraints used for prostate patients is
shown below in Table 2-1.

Structure
Rectum

Bladder

Clinical DVH
Constraints
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Table 2-1. MDACC clinical DVH planning constraints for external photon beam treatment of the prostate.

These five plans were optimized in Eclipse version 8.6 (Varian Medical Systems,
Palo Alto, CA) without the couch or rails included in the plans. This will be referred to as
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the IMRT clinical scenario plans because ignoring the couch is the standard clinical
situation. The Eclipse TPS IMRT optimization algorithm uses inverse-planning based on
DVH constraint inputs to calculate the MU’s and dynamic MLC pattern for each IMRT
field. The MLC leaf motion pattern was calculated using version 8.6.15 of the leaf motion
calculation algorithm in Eclipse.

The final dose was calculated using the Anisotropic

Analytical Algorithm (AAA), which is a 3D pencil beam convolution algorithm that uses
Monte Carlo derived models for primary and scattered photons. Plan normalization, when
necessary, was performed by normalizing the plan for PTV coverage. All plans were
generated using machine parameters for the same Varian Clinac linear accelerator.
To evaluate the effects of the couch top and rails, the clinical scenario plans were
copied and the couch top and rail structures were inserted into the plan in the following
configurations for a total of three additional plans for each patient:
1. Imaging insert and rails in the out position (referred to as the “rails out” plan),
representing a scenario in which the rails are not moved during treatment
2. Imaging insert and rails in the in position (referred to as the “rails in” plan), also
representing a scenario in which the rails are not moved during treatment
3. Imaging insert only (referred to as the “couch top only” plan), representing a
scenario where the rails are moved to avoid the beam during IMRT delivery
A sample image of the IMRT beam arrangement for one patient’s IMRT rails out and rails
in plans are shown below in Figure 2-2.
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Figure 2-2. 8-Field Beam Arrangement for IMRT with Imaging Couch Top and Rails. Rails Out (left panel),
Rails In (right panel).

After insertion of the couch top and/or rail structures, the AAA algorithm was used
to recalculate the final dose to the structures. These plans with the couch and/or rail
structures were then renormalized so that the MU’s of the plan matched the MU’s of the
clinical scenario plan. For 4 of the IMRT plans it was possible to renormalize such that there
was a 0% difference between the MUs between plans, to machine precision. For 1 patient
there was residual mismatch of 4 MUs for a total difference of 0.35% between the total
MU’s of the clinical scenario and the subsequent plans that included the couch and rails.
This renormalization was essential to ensure that any differences between the clinical
scenario plan and the couch plans would be solely attributable to the effect of the patient
support structures.
2.2.2

Varian RapidArc Planning

The VMAT delivery used in this study was Varian’s RapidArc (Varian Medical
Systems, Palo Alto, CA), which was planned in Eclipse version 8.6. The same five patients
that were planned with IMRT were also planned with RapidArc. All patients were planned
using the same parameters and constraints as the IMRT plans listed in the previous section.
Two arcs were used for all the plans; one arc field beginning at a gantry rotation of 180.1
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degrees and rotating to 179.9 degree clockwise with a 30 degree collimator rotation, and the
other beginning at 179.9 degrees and rotating to 180.1 degrees counter clockwise with a 330
degree collimator rotation. The couch rotation was set to 0 degrees for both fields and
neither the couch top nor the rails were included in the optimized plan per clinical practice.
The X and Y jaws were adjusted as needed on the beam’s eye view to encompass the target
before optimization. Varian’s RapidArc Progressive Resolution Optimizer (PRO) algorithm
was used to optimize the plans, as developed from the work by Karl Otto using inverseplanning based on dose-volume input constraints. The result is a dynamic MLC pattern,
variable gantry rotation, and variable dose rate. The final dose distribution is calculated
using the AAA algorithm. A sample clinical scenario RapidArc beam arrangement is shown
below in Figure 2-3.

Figure 2-3. Sample 2-field RapidArc beam arrangement

To evaluate the effects of the couch top and rails, these RapidArc clinical scenario
plans were copied and the couch top and rail structures were inserted into the plan in the
following configurations for a total of three additional plans for each patient’s clinical
scenario plan:
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1. Imaging insert and rails in the out position (referred to as the “rails out” plan),
representing a scenario in which the rails are not moved during treatment
2. Imaging insert and rails in the in position (referred to as the “rails in” plan), also
representing a scenario in which the rails are not moved
3. Imaging insert only (referred to as the “couch top only” plan). This scenario is
not clinically achievable in arc therapy but was evaluated for RapidArc to assess
the effect of the couch top and rails individually.
A sample image of the RapidArc beam arrangement for one patient’s rails out and rails in
plans are shown below in Figure 2-4.

Figure 2-4. 2-arc beam arrangement for RapidArc with the couch top and rails. Left panel shows rails out plan
and right panel shows rails in plan.

After insertion of the couch top and/or rail structures, the AAA algorithm was used
to calculate the final dose to the structures. These plans with the couch and/or rail structures
were then renormalized so that the MU’s of these plans matched exactly the MU’s of the
clinical scenario plan for each patient. This was to ensure that any differences between the
clinical scenario and these plans would be solely attributable to the effect of the patient
support structures.
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2.2.3 Varian Exact Couch
The Varian Exact couch (Varian Medical Systems, Palo Alto, CA) is positioned with
respect to the Varian linear accelerator it is associated with such that the couch lateral,
longitudinal, and rotational coordinates are displayed on the linac and within the linac’s
treatment console display. The couch is composed of the following components: hand
pendants to control the motion of the linac and its components, a lift base to raise and lower
the couch, removable end panels that can be used to attach patient immobilization devices,
movable structural rails to support the couch top panel, and removable flat panel (imaging
couch top) and unipanel (mesh couch top) treatment insert structures (15). The imaging
couch top and support rails are shown below in Figure 2-5 and Figure 2-6.

Figure 2-5. Varian Exact imaging couch top and support rails

Figure 2-6. Movable support rails on Varian Exact Couch
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The Exact Couch structures (various couch tops and movable support rails) are
available as insertable structures in the Eclipse TPS. The dimensions (i.e. thickness and CT
number) of these structural components are the same as the manufacturer’s specifications
and the densities of the structures are included in HU numbers assigned to each couch
component. The default settings for the couch components in the Eclipse TPS were used in
this study.
2.3 Point Dose Evaluation
2.3.1 Plan Verification: IMRT QA
The clinical IMRT QA protocol at MDACC was used to evaluate the point dose
agreement between the measured point dose in the IMRT QA hybrid phantom for the
clinical scenario IMRT and RapidArc plans and the expected dose calculated in the TPS in
the hybrid QA phantom. The clinical passing criterion at MDACC requires the dose
measurement and calculated by the TPS in the hybrid phantom to match within + 3%. A CT
image set of the IMRT QA phantom (IBA Dosimetry Bartlett, TN) with CC04 ion chamber,
inner radius of 2 mm, and a sensitivity of 94 x 107 Gy/C (IBA Dosimetry Bartlett, TN) was
imported into the Eclipse TPS and set as the default image for IMRT QA verification plans.
The active volume of the ion chamber was contoured so that doses to the ion chamber could
be calculated for a given plan.
To calculate the point dose in the Eclipse TPS, a verification plan was made for each
clinical scenario plan and additional plan that included the couch top and/or rails. The
verification plan was created by copying the IMRT or RapidArc plan onto the image of the
hybrid phantom and re-calculating the dose-volume with the same fluence and MU’s as the
19

original plan, which was achieved by using the same percent normalization for the hybrid
plans as was used for the clinical plans. A sample RapidArc clinical scenario hybrid plan is
shown below in Figure 2-7.

Figure 2-7. Sample hybrid plan for clinical scenario RapidArc plan

To calculate the dose to the plans that were modified by including the couch top and
rails, the couch top and rails were imported into the verification plan and then the plans were
recalculated with the AAA algorithm. Again, to maintain the same MU’s as the clinical
scenario plan with the couch and rails included, the hybrid plans were normalized to the
same value as the patient plans that included the couch and rail. The calculated dose to the
hybrid phantom’s ion chamber was recorded for each plan for comparison to measured
values. A sample RapidArc rails out hybrid plan is shown below in Figure 2-8.

Figure 2-8. Sample hybrid plan for RapidArc with imaging couch top and rails
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Point dose measurements for comparison to the calculated doses were made by
following the IMRT QA procedure at MDACC. First, a dose factor for the machine output
was needed to convert ion chamber measurements to dose. To get this factor, the IMRT QA
phantom was positioned on the Varian Exact treatment couch and aligned with the
machine’s lasers such that the active volume of the ion chamber was at isocenter. The field
size was set to 10 x 10 cm2, the machine set to 200 MU using a 6 MV photon beam. Three
readings were recorded with the gantry at each of 90 and 270 degrees, and the results were
averaged. That average ion chamber reading was then used to calculate the dose factor
using Equation 2-2 assuming a transfer factor of 113.2 cGy for a 6-MV photon beam.

Equation 2-2. MDACC clinical IMRT QA dose factor equation

Because the clinical scenario plans had the same MUs as their respective iterations
that included the couch and rails, the fields for the clinical-scenario plan was exported from
Eclipse and scheduled in Mosaiq for delivery on a Varian Clinac iX linac. Each patient plan
(5 IMRT and 5 Rapid Arc plans) was delivered twice; once with the rails in and once with
the rails in the out position. No measurement was taken without the couch top or rails as
this is not clinically feasible. The ion chamber reading for each field was recorded,
converted to dose using the dose factor, and summed (8 fields for IMRT and 2 fields for
RapidArc) to compare to the absolute point dose calculation from the Eclipse TPS.
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Comparisons between calculated and measured values for the IMRT and RapidArc
point dose measurements were made by evaluating the percent difference between the
calculated and measured value of interest using Equation 2-3.

Equation 2-3. Percent difference equation

2.4 DVH Analysis
2.4.1 Dose
Evaluation of the dosimetric impact of the couch top and rails was performed using
the tabular DVH information generated by each plan in the Eclipse TPS. The tabular DVH
information containing the absolute volume versus absolute dose for each structure of
interest was exported and evaluated using Excel. Information about the minimum,
maximum, and mean dose to each structure was exported along with the DVH information.
The impact of the couch top and rails on dose to the prostate and PTV were evaluated by
subtracting the minimum, maximum, and mean dose for each structure in the plans with the
couch top or rails from the respective structure in the clinical scenario plan for both IMRT
and RapidArc. This subtraction did not represent difference between the same two spatial
locations within a structure for different plans, but rather, the difference between the
maximums, minimums, and means without respect to spatial location within a structure.
Spatial information about dose differences was obtained graphically with plan
subtractions. The dose distribution for each plan with patient support structures was
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subtracted from the dose distribution of the clinical scenario plan and displayed visually on
the patient CT image, providing a visual image of the spatial distributions of dose
differences. However, this spatial information was not exportable using Eclipse.
2.4.2 Relative volume coverage
The relative volume coverage for the prostate, PTV, bladder, and rectum were
evaluated by calculating the relative volume of the structure covered by each dose bin. The
total absolute volume of a given structure was set to the volume of the structure covered at
the 0 Gy dose bin. The relative volume was then calculated by taking the ratio of the
absolute volume of the structure at each dose bin divided by the absolute volume covered at
the 0 Gy dose bin as shown in Equation 2-4.

Equation 2-4. Equation for relative volume

Where x is the volume of the structure covered by a dose of at least x.
2.5 Tumor Control Probability (TCP)
2.5.1 Niemierko and Goitein TCP Model
The TCP for each plan was calculated using an available script (16). This script is
based on a clinically implementable TCP model previously developed by Niemierko and
Goitein (17) for an inhomogeneously irradiated tumor derived from principles of
mechanistic cell kill and Poisson statistics. The script uses Equation 2-5 to calculate the TCP
using a differential DVH:
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Equation 2-5. Niemierko and Goitein TCP equation

TCD50 is the dose to the tumor needed to control 50% of the tumor cells when it is
homogeneously irradiated, and γ50 is a unitless parameter that describes the slope of the
dose-response curve at the value for TCD50. Both the TCD50 and γ50 parameters are obtained
from fitting clinical outcome data to dose-response curves. The last parameter into the TCP
equation is the equivalent uniform dose (EUD) which is the biologically equivalent dose
that, if given uniformly, will lead to the same cell kill in the tumor volume as the actual nonuniform dose distribution. The EUD is calculated using input DVH information as shown in
Equation 2-6.

Equation 2-6. Equivalent uniform dose (EUD) equation used in Niemierko and Goitein TCP model

Where Vi and Di are quantities from the input DVH information; specifically, Vi is unitless
and represents the ith partial volume receiving a dose of Di. The parameter ‘a’ is a unitless
parameter that is specific to the tumor of interest and describes the dose-volume effect.
Additional inputs into script are required that are not seen in the equations above.
Values for α/β, which describes the steepness of the dose-response curve, and the dose
fractionation of the plans are required inputs since they were used to fit the clinical-response
data from which TCD50 and γ50 were obtained. User inputs into the script included the DVH

24

information from which the EUD was calculated, a value for ‘a’, TCD50, γ50, α/β, and the
dose fractionation of the patient outcome cases used to derive the input parameters.
Values for dose-response-dependant parameters mentioned above were taken from
studies by Levegrun et al and Wu et al. Levegrun et al fit the dose-response data of 103
prostate cancer patients with 2 Gy treatment fractions to obtain values for TCD50 and γ50 for
low, intermediate, and high risk prostate cancer patients using the assumptions of the
Niemierko model (18). The value for ‘a’of -10 was taken from a study evaluating prostate
cancer cases with this model by Wu et al (19). The value of α/β of 10 Gy was used as it is a
common value associated with prostate tumors, however, as noted in the literature, reported
values can be as low as 1.5 Gy (18). Assuming an intermediate-risk patient population, we
used a TCD50 of 67.75 Gy, with a corresponding γ50 of 3.6, an α/β of 10 Gy, and fractions of
2-Gy.
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Chapter 3 Results
3.1 Relative Attenuation Versus Gantry Angle
The measured attenuation of the beam by the couch as a function of gantry angle is
shown in Figure 3-1 below, and in tabular form in Table 3-1. Relative attenuation was
normalized to 0 degrees, corresponding to an anterior beam.

Figure 3-1. Relative attenuation of Varian Exact couch tops and rails
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Gantry
Angle
0
90
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
270

Relative Attenuation
(%) Mesh Top, Rails
Out
0.0%
0.6%
0.6%
0.8%
1.1%
-12.0%
-17.1%
-3.5%
-4.3%
-9.6%
0.7%
0.4%
N/A
N/A
N/A
N/A
N/A
N/A
1.0%
N/A
N/A
N/A
N/A
N/A
N/A
0.2%
0.5%
-10.0%
-5.1%
-4.4%
-17.5%
-12.1%
0.7%
0.2%
0.2%
0.1%

Relative Attenuation
(%) Imaging Top,
Rails Out
0.0%
0.1%
0.2%
0.2%
0.7%
-5.0%
-21.8%
-7.7%
-7.7%
-12.6%
-2.2%
-1.9%
-1.7%
N/A
-1.3%
N/A
-1.4%
N/A
-1.3%
N/A
-1.2%
N/A
-1.3%
N/A
N/A
-1.9%
-2.1%
-13.2%
-7.9%
-8.3%
-20.5%
-4.8%
0.4%
-0.1%
0.1%
0.0%

Relative Attenuation
(%) Imaging Top, Rails
In
0.0%
0.1%
0.3%
0.4%
0.8%
-4.7%
-4.4%
-3.7%
-2.9%
-2.3%
-1.9%
-1.1%
-0.9%
N/A
-11.5%
-12.3%
-12.3%
-5.5%
0.0%
-3.3%
-12.6%
-14.3%
-11.6%
-10.5%
-1.0%
-1.3%
-1.8%
-2.5%
-2.9%
-3.7%
-4.6%
-5.2%
0.6%
0.2%
0.3%
0.0%

Table 3-1. Relative attenuation of Varian Exact imaging and mesh top with rails. The pink highlighting
represents angles over which the couch top and rails intersected with the beam.

27

The relative attenuation was as large as 21.8% when both the Exact imaging insert
and rails were traversed in the rails out position. The relative attenuation of the mesh insert
was as large as 17.1% when the Exact mesh insert and rails were both traversed in the rails
out position. The relative attenuation was as large as 14.3% when the Exact mesh insert and
rails were traversed in the rails in position.
3.2 IMRT and RapidArc Plans
3.2.1 IMRT DVH’s
The DVH’s for each patient’s IMRT plans (clinical scenario, rails out, rails in,
imaging couch only) are displayed below in Figure 3-2 through Figure 3-6. They are
displayed as relative structure volume versus absolute dose with the scale begins at 50 Gy
(5000 cGy) for all the plans to better visualize the areas of difference between the plans. A
full view of the entire DVH’s for these plans can be seen in the appendix. The PTV,
prostate, rectum, and bladder are displayed in blue, red, green, and yellow in each figure,
respectively. Each clinical scenario plan, which is the outer most pair of prostate and PTV
lines in each plan, passed MDACC’s planning criteria of at least 98% coverage of the
prostate and 95% coverage of the PTV by the prescription dose of 76 Gy. The next pair of
PTV and prostate DVH lines (those shifted to the left but closest to the clinical scenario) are
for both the plans with the rails in and the imaging couch top only for all patients. This
indicates that the loss of coverage to the structures is a result of the effects of the imaging
couch top alone and that the rails are not intersected in this position for this treatment beam
arrangement as shown in Figure 2-2 in section 2.2.1. The left-most set of prostate and PTV
DVH lines, the greatest dose reduction from the clinical scenario, are for the plan with the
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rails out in all the patients. This indicates that the most coverage to the target structures is
lost when both the imaging couch top and rails are intersected (as is shown in Figure 2-2).
The effect to the critical structures is harder to visualize with this scale on the DVH’s
and will be addressed separately in 3.4.3 Critical Structures: IMRT.

Figure 3-2. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient
1 showing structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and
bladder are displayed in blue, red, green, and yellow, respectively
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Figure 3-3. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient
2 showing structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and
bladder are displayed in blue, red, green, and yellow, respectively

Figure 3-4. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient
3 showing structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and
bladder are displayed in blue, red, green, and yellow, respectively
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Figure 3-5. DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient
4 showing structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and
bladder are displayed in blue, red, green, and yellow, respectively

Figure 3-6 DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient 5
showing structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and bladder
are displayed in blue, red, green, and yellow, respectively

31

3.2.2 IMRT MU’s
The MU’s used for each patient's IMRT clinical scenario plan and all subsequent
iterations of the plan including the couch top and rails is displayed below in Figure 3-7 as a
function of beam angle. For the one patient whose MUs were only able to be renormalized
within 0.35% when the couch and rails were included (patient 3, as mentioned in section
2.2.1), the renormalized MUs, as compared to the clinical scenario plan, resulted in the
fields at 295, 260, 135, and 100 degrees that were higher by 1 MU each as compared to the
clinical scenario MU’s. The trends analysis of this patient’s plans was consistent with the
other plans and this error was, therefore, not considered to impact the results.

Figure 3-7. TPS optimized MU’s for each gantry angle ssed for IMRT plans
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Most of the MUs were typically delivered at 330 and 30 degrees (e.g Patients 3,4,
and 5), corresponding to anterior directions. There were typically a minimal of MUs
delivered through lateral directions at 295 and 65 degrees (eg Patients 2, 3, and 4). However,
this was not universally true as patient 1 had a nearly inverted trend and patient 5 had more
MU’s through the lateral angles than the posterior angles at 225 and 135 degrees.
The number of MU’s per field varied for each patient. This is to be expected as the
patient size and specific anatomical properties varied and the TPS optimization is patientspecific to these variables in addition to the constraint parameters. The numerical MU
values for each patient’s plans are displayed below in Table 3-2 through Table 3-6, below.
Patient 1

Beam Angle
225
260
295
330
30
65
100
135

Clinical
Scenario MU
98
102
96
83
85
98
103
98

Rails Out
MU
98
102
96
83
85
98
103
98

Rails In MU
98
102
96
83
85
98
103
98

Imaging
Couch Top
Only MU
98
102
96
83
85
98
103
98

Plan
Normalization:

100% to 98%
of PTV

94.1%

94.1%

94.1%

Table 3-2. MU and normalization values for each plan iteration for patient 1
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Patient 2

Beam Angle
225
260
295
330
30
65
100
135

Clinical
Scenario MU
148
127
95
129
130
100
126
132

Rails Out
MU
148
127
95
129
130
100
126
132

Rails In MU
148
127
95
129
130
100
126
132

Imaging
Couch Top
Only MU
148
127
95
129
130
100
126
132

Plan
Normalization:

100% to 96%
of PTV

94.6%

94.6%

94.6%

Table 3-3. MU and normalization values for each plan iteration for patient 2

Patient 3

Beam Angle
225
260
295
330
30
65
100
135
Plan
Normalization:

Clinical
Scenario MU
94
101
88
134
122
88
112
98
100% to 96%
of PTV

Rails Out
MU
94
102
89
134
122
88
113
99

Rails In MU
94
102
89
134
122
88
113
99

Imaging
Couch Top
Only MU
94
102
89
134
122
88
113
99

94.6%

94.6%

94.6%

Table 3-4. MU and normalization values for each plan iteration for patient 3. The numbers in bold are the
angles that differed in MU compared to the clinical scenario plan.
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Patient 4

Beam Angle
225
260
295
330
30
65
100
135

Clinical
Scenario MU
137
92
72
152
137
77
96
113

Rails Out
MU
137
92
72
152
137
77
96
113

Rails In MU
137
92
72
152
137
77
96
113

Imaging
Couch Top
Only MU
137
92
72
152
137
77
96
113

Plan
Normalization:

100% to 96%
of PTV

93.5%

93.5%

93.5%

Table 3-5. MU and normalization values for each plan iteration for patient 4

Patient 5

Beam Angle
225
260
295
330
30
65
100
135

Clinical
Scenario MU
102
130
110
172
156
103
127
104

Rails Out
MU
102
130
110
172
156
103
127
104

Rails In MU
102
130
110
172
156
103
127
104

Imaging
Couch Top
Only MU
102
130
110
172
156
103
127
104

Plan
Normalization:

100% to 97%
of PTV

94.2%

94.2%

94.2%

Table 3-6. MU and normalization values for each plan iteration for patient 5

3.2.3 IMRT Sample Plans
A sample patient clinical scenario IMRT plan next to its subsequent iterations (rails
out, rails in, and couch top only) for the same CT slice are displayed below in Figures 3-8
through 3-10 with the same isodose lines. The clinical scenario plan slice on the left panel
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of each figure shows complete coverage of the prostate (in blue colorwash) by the 76 Gy
isodose line (in red), indicating complete coverage of the structure on that CT slice when the
couch and rails are not included in the plan, as is clinical practice at MDACC. The image in
the right panel show the changes in the prescription isodose coverage of the target when the
couch and rails are considered. Other representative plans are shown in the appendix.
Figure 3-8 below shows the isodose coverage of the prostate with the rails out as
compared to the coverage for the clinical scenario on the same CT slice; the prescription
isodose line is no longer covering the prostate as it was in the clinical scenario plan. This
‘breaking’ of the prescription isodose line would not be clinically acceptable for plan
approval.

Figure 3-8. Clinical scenario IMRT plan (left panel) and plan with rails out (right panel) for patient 3 with
prostate shown in blue colorwash

Figure 3-9 below shows the isodose coverage of the prostate with the rails in; the
prescription isodose line is no longer completely covering the prostate as it was in the
clinical scenario plan. This ‘breaking’ of the prescription isodose line is less drastic than it
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was for the rails out configuration (Figure 3-8), but may still not be clinically acceptable for
plan approval.

Figure 3-9. Clinical scenario IMRT plan (left panel) and plan with rails in (right panel) for patient 3 with
prostate shown in blue colorwash

Figure 3-10 below shows the isodose coverage of the prostate with the imaging
couch top only; the prescription isodose line is no longer completely covering the prostate as
it was in the clinical scenario plan. Again, this ‘breaking’ of the prescription isodose line
may not be clinically acceptable for plan approval.

Figure 3-10. Clinical scenario IMRT plan (left panel) and plan with imaging couch only (right panel) for
patient 3 with prostate shown in blue colorwash
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3.2.4 IMRT Sample Plan Subtractions
The same patient plans displayed in section 3.2.3 are displayed below as plan
subtractions in Figure 3-11 through Figure 3-13 to show areas of dose loss between the
clinical scenario and plans that include the couch and rails. The figures represent the spatial
areas and magnitudes of dose loss between the clinical scenario and the plans that account
for various components and configurations of the couch and rails. For all the subtractions
shown, the red isodose line represents a loss of 110 cGy and each subsequent line represents
5 cGy less than the previous line, ending with the navy blue line representing a dose loss of
80 cGy. Other representative plans are shown in the appendix.
Figure 3-11 below shows a representative result for an IMRT plan subtraction
between the rails out plan and the clinical scenario. The path of the dose loss appears to be
along the path of the posterior beams in the 8-field beam arrangement shown in Figure 2-2
in section 2.2.1, and encompasses the entire volume of the prostate target.

Figure 3-11. Clinical scenario IMRT plan subtracted from rails out plan for patient 3 with prostate shown in
blue colorwash
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Figure 3-12 below shows a representative result for an IMRT plan subtraction
between the rails in plan and the clinical scenario. The path of the dose loss again follows
the path of the posterior beams in the 8-field beam arrangement shown in Figure 2-1 in
section 2.2.1, and again encompasses the entire volume of the prostate on this CT slice.
However, the doss loss has a different pattern and magnitude of as compared to the previous
figure for the rails out plan. This is expected because the rails are not traversed by either of
the posterior beams in our standard beam arrangement; only the couch top is intersected for
the posterior fields as shown in Figure 2-2 in section 2.2.1.

Figure 3-12. Clinical scenario IMRT plan subtracted from rails in plan for patient 3 with prostate shown in
blue colorwash

Figure 3-13 below shows a representative result for an IMRT plan subtraction
between the imaging couch top only plan and the clinical scenario. The dose loss is the
same in appearance as the rails-in subtraction in the previous figure. This is expected
because only the couch top is intersected for the posterior fields with the rails in as shown in
Figure 2-2 in section 2.2.1.
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Figure 3-13. Clinical scenario IMRT plan subtracted from imaging couch top only plan for patient 3 with
prostate shown in blue colorwash

3.2.5 RapidArc DVH’s
The DVH’s for each patient’s RapidArc plans (clinical scenario, rails out, rails in,
imaging couch only) are displayed below. They are displayed as relative structure volume
versus absolute dose and the scale begins at 50 Gy (5000 cGy) for all the plans to better
visualize the areas of difference between the plans. A full view of the entire DVH’s for
these plans can be seen in the appendix. The PTV, prostate, rectum, and bladder are
displayed in blue, red, green, and yellow in each figure, respectively. Each clinical scenario
plan, which is the outer most pair of prostate and PTV lines in each plan passed MDACC’s
planning criteria of at least 98% coverage of the prostate and 95% coverage of the PTV by
the prescription dose of 76 Gy. The next pair of PTV and prostate DVH lines (shifted to the
left and closest to the clinical scenario) are for the imaging couch top only for all patients
and indicate that the couch top itself contributes to coverage loss to target structures. The
left-most two sets of prostate and PTV DVH lines (with the greatest reduction in coverage
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from the clinical scenario) are for the plans with the rails out and rails in for all the patients.
The rails out and rails in target DVH lines are very close and sometimes overlapping. This is
reasonable because, as the beam arrangement shows in Figure 2-4 in section 2.2.2, both the
couch top and rails are intersected during delivery in all rail configurations. Figures 3.14 to
3.18 indicate that both the imaging couch top and rails contribute to target dose loss.
The effect to the critical structures is harder to visualize with this scale on the DVH’s
and will be addressed separately in 3.6.3 Critical Structures: RapidArc.

Figure 3-14. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for
patient 1 structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and bladder
are displayed in blue, red, green, and yellow, respectively.
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Figure 3-15. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for
patient 2 structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and bladder
are displayed in blue, red, green, and yellow, respectively.

Figure 3-16. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for
patient 3 structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and bladder
are displayed in blue, red, green, and yellow, respectively.
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Figure 3-17. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for
patient 4 structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and bladder
are displayed in blue, red, green, and yellow, respectively.

Figure 3-18. DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for
patient 5 structures as a function of relative volume and absolute dose. The PTV, prostate, rectum, and bladder
are displayed in blue, red, green, and yellow, respectively.
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3.2.6 RapidArc MU’s
The MUs used for each patient RapidArc clinical scenario plan and all subsequent
iterations of the plan including the couch top or rails are displayed below in Table 3-7 for
each of the two fields with 30 and 330 degree collimator rotations. The MUs for the clinical
scenario plans were identical to subsequent iterations of the plans that included the couch
and rails.

Patient
1
1
2
2
3
3
4
4
5
5

Collimator
Rotation
30
330
30
330
30
330
30
330
30
330

MU
320
343
483
430
488
480
293
284
550
613

Table 3-7. The TPS optimized MU’s for the two arc fields for RapidArc plans

The MUs and normalization values for each patient’s plans are displayed below in
Table 3-8 through Table 3-12.
Patient 1
Collimator
Rotation
30
330

Clinical
Scenario MU
320
343

Rails Out
MU
320
343

Rails In MU
320
343

Imaging
Couch Top
Only MU
320
343

Plan
Normalization:

100% to 98%
of PTV

100.0%

100.0%

100.0%

Table 3-8. MUs and normalization values for each plan iteration for patient 1
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Patient 2
Collimator
Rotation
30
330

Clinical
Scenario MU
320
343

Rails Out
MU
320
343

Rails In MU
320
343

Imaging
Couch Top
Only MU
320
343

Plan
Normalization:

100% to 98%
of PTV

100.0%

100.0%

100.0%

Table 3-9. MUs and normalization values for each plan iteration for patient 2

Patient 3
Collimator
Rotation
30
330

Clinical
Scenario MU
320
343

Rails Out
MU
320
343

Rails In MU
320
343

Imaging
Couch Top
Only MU
320
343

Plan
Normalization:

100% to 95%
of PTV

100.0%

100.0%

100.0%

Table 3-10. MUs and normalization values for each plan iteration for patient 3

Patient 4
Collimator
Rotation
30
330

Clinical
Scenario MU
320
343

Rails Out
MU
320
343

Rails In MU
320
343

Imaging
Couch Top
Only MU
320
343

Plan
Normalization:

100% to 98%
of PTV

100.0%

100.0%

100.0%

Table 3-11. MUs and normalization values for each plan iteration for patient 4

Patient 5
Collimator
Rotation
30
330

Clinical
Scenario MU
320
343

Rails Out
MU
320
343

Rails In MU
320
343

Imaging
Couch Top
Only MU
320
343

Plan
ormalization:

100% to 98%
of PTV

100.0%

100.0%

100.0%

Table 3-12. MUs and normalization values for each plan iteration for patient 5
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3.2.7 RapidArc Sample Plans
A sample patient clinical scenario RapidArc plan next its subsequent iterations (rails
out, rails in, and couch top only plans) for the same CT slice are displayed below in Figure
3-19 through Figure 3-21 for the same isodose lines. The clinical scenario on the left panel
of each figure shows complete coverage of the prostate (in blue colorwash) by the 76 Gy
isodose line (in red), showing complete coverage of the structure on that CT slice when the
couch and rails are not included in the plan, as is clinical practice at MDACC. The image in
the right panel show the changes in the prescription isodose coverage of the target when the
couch and rails are considered. Other representative plans are shown in the appendix.
Figure 3-19 below shows the isodose coverage of the prostate with the rails out as
compared to the coverage for the clinical scenario on the same CT slice; the prescription
isodose line is no longer covering the prostate as it was in the clinical scenario plan. This
‘breaking’ of the prescription isodose line would not be clinically acceptable for plan
approval.

Figure 3-19. Clinical scenario RapidArc plan (left panel) and rails out plan (right panel) for patient 3 with
prostate shown in blue colorwash
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Figure 3-20 below shows the isodose coverage of the prostate with the rails in as
compared to the coverage for the clinical scenario on the same CT slice; the prescription
isodose line is no longer covering the prostate as it was in the clinical scenario plan. This
‘breaking’ of the prescription isodose line is similar to the rails out configuration and would
also not be clinically acceptable for plan approval.

Figure 3-20. Clinical scenario RapidArc plan (left panel) and rails in plan (right panel) for patient 3 with
prostate shown in blue colorwash

Figure 3-21 below shows the isodose coverage of the prostate with the imaging couch
top only as compared to the coverage for the clinical scenario on the same CT slice; the
prescription isodose line is no longer covering the prostate as it was in the clinical scenario
plan. This ‘breaking’ of the prescription isodose line is less than when the rails were also
included and may not be clinically acceptable for plan approval.
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Figure 3-21. Clinical scenario RapidArc plan (left panel) and imaging couch only plan (right panel) for
patient 3 with prostate shown in blue colorwash

3.2.8 RapidArc Sample Plan Subtractions
The same patient plans displayed in section 3.2.3 are displayed below as plan
subtractions in Figure 3-22 through Figure 3-24 to show areas and magnitudes of dose loss
between the clinical scenario and plans that include the couch and rails. For all the
subtractions shown, the red isodose line represents a loss of 110 cGy and each subsequent
line represents 5 cGy less than the previous line, ending with the navy blue line representing
a dose loss of 80 cGy. Other representative plans are shown in the appendix.
Figure 3-22 below shows a representative result for a RapidArc plan subtraction
between the rails out plan and the clinical scenario. The path of the dose loss is along the
length of the couch and not as narrow as the IMRT plan subtraction in Figure 3-11 in section
3.2.4 because the delivery of dose is continuous during RapidArc delivery for all gantry
angles and not fixed as in IMRT. The area of dose loss encompasses the entire volume of
the prostate target and has the largest magnitude along the path of the rails.
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Figure 3-22. Clinical scenario RapidArc plan subtracted from rails out plan for patient 3 with prostate shown
in blue colorwash

Figure 3-23 below shows a representative result for a RapidArc plan subtraction
between the rails in plan and the clinical scenario. The pattern of dose loss is also spatially
different from the rails out subtraction shown in the previous figure and is due to the
differing rail position. The area of dose loss encompasses the entire volume of the prostate
target has the largest magnitude along the path of the rails.
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Figure 3-23. Clinical scenario RapidArc plan subtracted from rails in plan for patient 3 with prostate shown in
blue colorwash

Figure 3-24 below shows a representative result for a RapidArc plan subtraction
between the imaging couch top only plan and the clinical scenario. The pattern of dose loss
is also spatially different from both the rails out and rails in subtraction shown in the two
previous figures and shows only the dose lose contribution from the couch top. The area of
dose loss encompasses the entire volume of the prostate target.
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Figure 3-24. Clinical scenario RapidArc plan subtracted from the imaging couch top only plan for patient 3
with prostate shown in blue colorwash

3.3 Dosimetric Accuracy Evaluation
3.3.1 Absolute Point Dose Analysis: TPS Couch Model Validation
The results for the first goal of specific aim 2, to evaluate the ability of the Eclipse
TPS to predict the dose perturbation caused by the couch and rails, are shown below in
Table 3-13 and Table 3-14 for all of the IMRT and RapidArc plans.
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Patient
1
2
3
4
5
1
2
3
4
5

Plan Delivery
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails In
IMRT--Rails In
IMRT--Rails In
IMRT--Rails In
IMRT--Rails In

Predicted Dose
(Hybrid Plan) (cGy)
221.8
214.0
199.2
203.3
238.8
226.5
219.4
204.2
209.7
244.0

Measured Dose
(cGy)
220.8
211.9
199.4
201.4
237.7
226.1
218.9
205.2
210.8
244.9

% Difference
0.5%
1.0%
0.1%
1.0%
0.5%
0.2%
0.2%
0.5%
0.5%
0.4%

Table 3-13. TPS-calculated dose for IMRT plans including the couch and rails compared to the measured
dose for specified plan delivery.

Patient
1
2
3
4
5
1
2
3
4
5

Plan Delivery
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails In
Rapid Arc--Rails In
Rapid Arc--Rails In
Rapid Arc--Rails In
Rapid Arc--Rails In

Predicted Dose
(Hybrid Plan) (cGy)
218.0
215.0
201.2
199.8
235.3
218.6
215.8
203.9
201.3
235.2

Measured Dose
(cGy)
218.4
211.2
200.6
202.5
235.5
219.1
219.5
202.8
203.1
234.4

% Difference
0.2%
1.8%
0.3%
1.3%
0.1%
0.2%
1.7%
0.5%
0.9%
0.3%

Table 3-14. TPS-calculated dose for RapidArc plans including the couch and rails compared to the actual
measured dose for specified plan delivery.

The average percent difference between absolute point dose measurements and TPS
hybrid calculations including the couch and rails was 0.6% and 0.4% for IMRT with the
rails out and rails in, respectively. The average percent difference between absolute point
dose measurements and TPS hybrid calculations including the couch and rails was 0.7% for
RapidArc with the rails out and rails in.
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3.3.2 Absolute Point Dose Analysis: Clinical QA Experience
The results for the second goal of specific aim 2, to evaluate the difference in dose
between measurements taken with the couch and rails in the IMRT QA phantom to the
absolute dose predicted by the Eclipse TPS when the couch and rails are not taken into
account, are shown in Table 3-15 and Table 3-16, for all IMRT and RapidArc plan
deliveries. These results reflect the difference between what we think is being delivered and
what we are delivering during our IMRT QA.

Patient
1
2
3
4
5
1
2
3
4
5

Plan Delivery
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails Out
IMRT--Rails In
IMRT--Rails In
IMRT--Rails In
IMRT--Rails In
IMRT--Rails In

Predicted Dose
(Clinical Scenario)
(cGy)
230.0
223.2
209.5
214.2
247.8
230.0
223.2
209.5
214.2
247.8

Measured Dose
(cGy)
220.8
212.7
199.4
201.4
237.7
226.1
218.9
205.2
210.8
244.9

% Difference
4.1%
4.8%
5.0%
6.2%
4.2%
1.7%
2.0%
2.1%
1.6%
1.2%

Table 3-15. TPS-calculated dose for IMRT plans not accounting for the couch and rails (clinical scenario)
compared to the measured dose with the couch and rails
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Patient
1
2
3
4
5
1
2
3
4
5

Plan Delivery
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails Out
Rapid Arc--Rails In
Rapid Arc--Rails In
Rapid Arc--Rails In
Rapid Arc--Rails In
Rapid Arc--Rails In

Predicted Dose
(Clinical Scenario)
(cGy)
218.4
215.0
200.6
202.5
235.5
219.1
215.8
202.8
203.1
234.4

Measured Dose
(cGy)
223.8
221.2
209.8
208.2
242.2
223.8
221.2
209.8
208.2
242.2

% Difference
2.4%
2.8%
4.5%
2.8%
2.8%
2.1%
2.5%
3.4%
2.5%
3.3%

Table 3-16. TPS-calculated dose for RapidArc plans not accounting for the couch and rails (clinical scenario)
compared to the measured dose with the couch and rails

The average percent difference between absolute point dose measurements including
the couch and rails and TPS hybrid calculations neglecting the couch and rails was 4.7% and
1.7% for IMRT with the rails out and rails in, respectively. The average percent difference
between absolute point dose measurements and TPS hybrid calculations was 3.0% and 2.7%
for RapidArc with the rails out and rails in, respectively.
The agreement was better on average and for each plan when the treatment couch
and rails were included in TPS hybrid calculations as shown below in 3-17. Most
importantly to note, all of the IMRT and RapidArc plans with the rails out would fail
MDACC’s IMRT QA passing criteria of + 3% agreement.
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Treatment modality
and configuration
IMRT
Rails out
Rails in
RapidArc
Rails out
Rails in

Difference including
couch and rails

Difference excluding couch
and rails (clinical scenario)

0.6%
0.4%

4.8%
1.7%

0.7%
0.7%

3.1%
2.7%

3-17. Average percentage differences between measured point doses and TPS-calculated point doses for hybrid
plans that included the couch and rails and plans that did not include these structures per normal IMRT QA
protocol.

3.4

DVH Analysis: IMRT
3.4.1 Volume Coverage to Prostate and PTV: IMRT
DVH analysis to evaluate the relative volume coverage of the prostate and PTV

target structures was performed using the DVH for each patient plan. Table 3-18 shows
target coverage for the clinical scenario plan. Target coverage for the plans with the rails
out, rails in, and imaging couch top only are shown in Table 3-19, through Table 3-21,
respectively. Lastly, Table 3-22 shows the average of the target coverage over all patients
for all the plan scenarios displayed in the preceding tables.
Clinical Scenario
Patient

1

2

3

4

5

Prostate % Volume Coverage at Rx
Dose

100%

100%

100%

100%

100%

PTV % Volume Coverage at Rx
Dose

98%

96%

96%

96%

97%

Table 3-18. Percent coverage of target structures for clinically optimized IMRT plans for each patient at
prescription dose of 76Gy
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Rails Out
Patient

1

2

3

4

5

Prostate % Volume Coverage at Rx
Dose

80%

54%

6%

35%

3%

PTV % Volume Coverage at Rx
Dose

77%

50%

17%

42%

11%

Table 3-19. Percent coverage of target structures for rails out IMRT plans at prescription dose of 76Gy

Rails In
Patient

1

2

3

4

5

Prostate % Volume Coverage at Rx
Dose

100%

80%

76%

99%

62%

PTV % Volume Coverage at Rx
Dose

95%

77%

71%

89%

64%

Table 3-20. Percent coverage of target structures for rails in IMRT plans at prescription dose of 76Gy

Imaging Couch Top
Patient

1

2

3

4

5

Prostate % Volume Coverage at Rx
Dose

100%

80%

77%

99%

62%

PTV % Volume Coverage at Rx
Dose

95%

77%

72%

89%

64%

Table 3-21. Percent coverage of target structures for imaging couch top only IMRT plans at prescription dose
of 76Gy

Plan Type:

Clinical
Scenario

Rails Out

Rails In

Imaging Couch Top
Only

Prostate Average % Volume
Coverage at Rx Dose

100%

35%

84%

84%

PTV Average % Volume
Coverage at Rx Dose

97%

39%

79%

79%

Table 3-22. Average relative volume coverage at prescription dose of 76 Gy to prostate and PTV target
structures for IMRT Plans with varying rail configurations

All of the clinical scenario plans met MDACC clinical approval criteria of 98%
coverage of the prostate and 95% of the PTV being covered by the prescription dose of
76Gy with an average of 100% coverage of the prostate and 97% coverage of the PTV at the
prescription dose of 76 Gy. The presence of the couch top and rails in vary configurations
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causes a loss in coverage that is, on average, unacceptable for plan approval. The individual
magnitudes of coverage loss for each of the five patients individually vary widely due to
differences in MU’s, patient size, and volume of target structures, which is expected in a
random patient population.
3.4.2

Dose Loss to Prostate and PTV: IMRT

The minimum, maximum, and mean dose loss to the target prostate and PTV
structures were obtained from the DVH data. The minimum, maximum, and mean doses to
the target structures in the plans with the couch and rails in varying configurations were
subtracted from the respective clinical scenario plans to obtain the absolute dose losses.
These values are displayed as the percentage of prescribed dose loss to the targets (76 Gy).
The dose losses for the rails out, rails in, and couch top only plans for all IMRT patients are
shown in Table 3-23, Table 3-24, and Table 3-25, respectively. Lastly, Table 3-26 shows
the average of the dose losses for all patients and plan types.
Rails Out
Patient
Prostate Min Dose Loss (%)
Prostate Max Dose Loss (%)
Prostate Mean Dose Loss (%)
PTV Min Dose Loss (%)
PTV Max Dose Loss (%)
PTV Mean Dose Loss (%)

1
4.9%
4.2%
4.3%
3.6%
3.6%
4.1%

2
3.6%
2.8%
3.7%
3.1%
2.7%
3.7%

3
5.2%
4.3%
5.1%
5.8%
4.6%
4.9%

4
4.9%
3.2%
4.1%
4.4%
3.4%
3.9%

5
4.3%
3.2%
3.9%
3.6%
3.0%
3.7%

Table 3-23. Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails out
plans for all IMRT patients’ target structures
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Rails In
Patient
Prostate Min Dose Loss (%)
Prostate Max Dose Loss (%)
Prostate Mean Dose Loss (%)
PTV Min Dose Loss (%)
PTV Max Dose Loss (%)
PTV Mean Dose Loss (%)

1
1.8%
1.6%
1.7%
0.9%
1.9%
1.7%

2
1.5%
1.4%
1.6%
1.6%
1.4%
1.7%

3
2.8%
2.8%
2.8%
2.6%
2.9%
2.8%

4
1.9%
1.6%
1.9%
1.2%
1.6%
1.8%

5
1.6%
1.6%
1.7%
1.5%
1.5%
1.6%

Table 3-24. Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails in
plans for all IMRT patients’ target structures

Imaging Couch Top
Patient
Prostate Min Dose Loss (%)
Prostate Max Dose Loss (%)
Prostate Mean Dose Loss (%)
PTV Min Dose Loss (%)
PTV Max Dose Loss (%)
PTV Mean Dose Loss (%)

1
1.8%
1.6%
1.7%
0.9%
1.9%
1.7%

2
1.5%
1.4%
1.6%
1.6%
1.4%
1.7%

3
2.8%
2.8%
2.8%
2.6%
2.9%
2.8%

4
1.9%
1.6%
1.9%
1.2%
1.6%
1.8%

5
1.6%
1.6%
1.7%
1.5%
1.5%
1.6%

Table 3-25. Minimum, maximum, and mean prescription dose loss between the clinical scenario and imaging
couch top only plans for all IMRT patients’ target structures

Plan Type:
Average Prostate Min Dose Loss (%)
Average Prostate Max Dose Loss (%)
Average Prostate Mean Dose Loss (%)
Average PTV Min Dose Loss (%)
Average PTV Max Dose Loss (%)
Average PTV Mean Dose Loss (%)

Rails Out
4.6%
3.5%
4.2%
4.1%
3.5%
4.1%

Rails In
1.9%
1.8%
2.0%
1.6%
1.9%
1.9%

Imaging Couch
Top Only
1.9%
1.8%
2.0%
1.5%
1.9%
1.9%

Table 3-26. Average prescription dose loss between the clinical scenario and plans with rails out, rails in, and
imaging couch top only for IMRT

On average, the dose loss to the prostate and PTV was greater for IMRT with the
rails out (typically 4%) than for rails in or the couch top alone (typically 2%). This is
expected because the rails are only traversed by the posterior fields when the rails are in the
out position. The average dose loss for the plans with the rails in is the same as for the
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couch top only; this is consistent with the DVH figures and plan subtractions in sections
3.2.1 and 3.2.4, respectively.
3.4.3 Critical Structures: IMRT
The results of analysis on the normal tissue structure volume of the rectum and
bladder receiving doses that are used as DVH constraints for treatment planning were
obtained from IMRT DVH information. Table 3-27 shows the critical structure volumedose information for all IMRT patients’ clinical scenario plans. The critical structure
volume-dose information for all IMRT patients’ rails out, tails in, and couch top only plans
are shown in Table 3-28, Table 3-29, and Table 3-30, respectively. Lastly, Table 3-31 shows
the average volume-dose data for all patients and plans.

Rectum

Bladder

Clinical
Scenario
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
44%
39%
25%
17%
12%
6%
5%

Patient 2
58%
48%
24%
15%
8%
0%
21%

Patient 3
40%
35%
23%
14%
5%
0%
13%

Patient 4
41%
31%
15%
9%
6%
0%
11%

Patient 5
45%
37%
20%
11%
5%
0%
10%

Table 3-27. Dose-volume data for each IMRT clinical scenario plan as a function of clinical DVH dosevolume constraints

Rectum

Bladder

Rails Out
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
42%
37%
23%
14%
6%
0%
5%

Patient 2
54%
43%
21%
12%
12%
0%
19%

Patient 3
38%
33%
21%
9%
0%
0%
11%

Patient 4
38%
29%
13%
8%
3%
0%
10%

Patient 5
41%
33%
18%
7%
0%
0%
9%

Table 3-28. Dose-volume data for each IMRT rails out plan as a function of clinical DVH dose-volume
constraints
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Rectum

Bladder

Rails In
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
43%
38%
24%
16%
10%
0%
5%

Patient 2
56%
46%
23%
13%
5%
0%
20%

Patient 3
39%
33%
21%
11%
1%
0%
12%

Patient 4
39%
30%
14%
8%
4%
0%
10%

Patient 5
43%
35%
19%
9%
3%
0%
10%

Table 3-29. Dose-volume data for each IMRT rails in plan as a function of clinical DVH dose-volume
constraints

Rectum

Bladder

Imaging Couch
Top
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
43%
38%
24%
16%
10%
0%
5%

Patient 2
56%
46%
23%
14%
5%
0%
20%

Patient 3
39%
33%
22%
11%
1%
0%
12%

Patient 4
39%
30%
14%
8%
4%
0%
10%

Patient 5
43%
35%
19%
9%
3%
0%
10%

Table 3-30. Dose-volume data for each IMRT imaging couch top only plan as a function of clinical DVH
dose-volume constraints

Rectum

Bladder

Averages
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Clinical
Scenario
45%
38%
21%
13%
7%
1%
12%

Couch with
Rails Out
42%
35%
19%
10%
4%
0%
11%

Couch with
Rails In
44%
36%
20%
12%
4%
0%
11%

Imaging
Couch Top
Only
44%
36%
20%
12%
4%
0%
11%

Table 3-31. Averaged dose-volume data for all IMRT plan iterations as a function of clinical DVH dosevolume constraints

On average, the rectum and bladder received less dose to their volumes when the
imaging couch top and/or rails were included in the plans. This indicates that when the
couch and rails are not included in treatment planning, the critical structures are receiving
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less dose than indicated by the clinical scenario which could have implications about the
validity of the current clinical DVH constraints that will discussed in the next chapter.
3.5 Tumor Control Probability: IMRT
3.5.1 TCP Results: IMRT
The DVH information from each IMRT patient’s plans (clinical scenario, rails out,
and rails in) was used along with the specific input parameters mentioned in section 2.5.1 for
the TCP model. Values for the imaging couch top only plan were not calculated as they
would be the same as the rails in plan. The results are shown below for all patients in Table
3-32 and averaged over all patients in Table 3-33.

IMRT TCP

Clinical
Scenario

Rails Out

Rails In

Patient 1

92%

85%

90%

Patient 2

89%

84%

86%

Patient 3

90%

80%

85%

Patient 4

91%

83%

88%

Patient 5

88%

79%

85%

Table 3-32. IMRT TCP results for each patient’s clinical scenario, rails out, and rails in plans

IMRT TCP

Clinical
Scenario

Rails Out

Rails In

90%

82%

87%

Table 3-33. IMRT TCP results averaged over all patients
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The IMRT TCP results show a reduction in predicted tumor control due to the
attenuation of the couch top and rails not being accounted for in treatment planning. While
clinically it is believed that 90% of patient tumors would be controlled with the developed
treatment plans, in fact, because less dose is being delivered, only 82% (rails out) or 87%
(rails in) of tumors would be controlled. The TCP reduction for each patient’s rails out
plans was greater than the loss predicted by the respective rails in plan. This trend is
consistent with the magnitudes of dose and volume loss shown in 3.4.1 and 3.4.2;
specifically that the rails out plans always had greater losses in mean dose and coverage to
the targets than the respective rails in plans.
3.6 DVH Analysis: RapidArc
3.6.1 Volume Coverage to Prostate and PTV: RapidArc
Similar to 3.4.1, the loss of target coverage was examined for RapidArc plans. The
results are shown below for the clinical scenario in Table 3-34. The results for the rails out,
rails in, and couch top only plans are shown in Table 3-35, Table 3-36, and Table 3-37,
respectively. Lastly, Table 3-38 shows the average target coverage losses for all RapidArc
plans and patients.
Clinical Plan
Patient
Prostate % Volume Coverage at Rx
Dose
PTV % Volume Coverage at Rx
Dose

1

2

3

4

5

98%

99%

100%

99%

98%

98%

98%

95%

98%

98%

Table 3-34. Percent prescription dose coverage of target structures for clinically optimized RapidArc plans
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Rails Out
Patient
Prostate % Volume Coverage at Rx
Dose
PTV % Volume Coverage at Rx
Dose

1

2

3

4

5

6%

30%

28%

24%

3%

39%

46%

26%

5%

21%

Table 3-35. Percent prescription dose coverage of target structures for rails out RapidArc plans

Rails In
Patient
Prostate % Volume Coverage at Rx
Dose
PTV % Volume Coverage at Rx
Dose

1

2

3

4

5

3%

28%

47%

1%

4%

29%

40%

31%

10%

22%

Table 3-36. Percent prescription dose coverage of target structures for rails in RapidArc plans

Imaging Couch Top
Patient
Prostate % Volume Coverage at Rx
Dose
PTV % Volume Coverage at Rx
Dose

1

2

3

4

5

37%

55%

75%

9%

24%

68%

72%

63%

27%

53%

Table 3-37. Percent prescription dose coverage of target structures for imaging couch top only RapidArc plans

Plan Type:

Clinical
Scenario

Couch with
Rails Out

Couch with
Rails In

Couch Top
Only

Prostate Average % Volume
Coverage at Rx Dose

99%

18%

17%

40%

PTV Average % Volume
Coverage at Rx Dose

97%

27%

26%

57%

Table 3-38. Average relative volume coverage at prescription dose of 76 Gy to prostate and PTV target
structures for RapidArc Plans with varying rail configurations

All of the clinical scenario plans met MDACC clinical approval criteria of 98% of
the prostate and 95% of the PTV being covered by the prescription dose of 76Gy with an
average of 99% coverage of the prostate and 97% coverage of the PTV. For all the plans
that included the couch and rails, the target coverage loss was substantial enough to cause a
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failure of clinical planning criteria. Similar losses in coverage for the rails out and rails in
plans were observed which was expected based on the DVH results shown previously. The
loss in coverage varied greatly between the five patients due to differences in MU’s, patient
size, and volume of target structures, which is expected in a random patient population.
3.6.2 Dose Loss to Prostate and PTV: RapidArc
Similar to section 3.4.2, the percentage of prescription dose lost for the PTV and
prostate target structures is shown for the RapidArc plans. Minimum, maximum, and mean
dose losses to the targets for the rails out, rails in, and couch top only plans for all patients
are shown in Table 3-39, Table 3-40, and Table 3-41, respectively. Lastly, Table 3-42
shows the average dose losses for all plans from the preceding tables.
Rails Out
Patient
Prostate Min Dose Loss (%)
Prostate Max Dose Loss (%)
Prostate Mean Dose Loss (%)
PTV Min Dose Loss (%)
PTV Max Dose Loss (%)
PTV Mean Dose Loss (%)

1
3.0%
2.5%
2.5%
3.0%
2.2%
2.5%

2
2.6%
1.5%
2.3%
3.3%
1.9%
2.5%

3
4.6%
3.5%
4.0%
4.3%
2.7%
3.9%

4
3.8%
2.9%
3.6%
4.1%
2.6%
3.5%

5
3.5%
2.7%
3.5%
3.4%
2.3%
3.4%

Table 3-39. Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails out
plans for RapidArc patients’ target structures

Rails In
Patient
Prostate Min Dose Loss (%)
Prostate Max Dose Loss (%)
Prostate Mean Dose Loss (%)
PTV Min Dose Loss (%)
PTV Max Dose Loss (%)
PTV Mean Dose Loss (%)

1
3.1%
2.6%
2.7%
3.1%
2.2%
2.8%

2
2.6%
1.6%
2.2%
2.7%
2.2%
2.6%

3
4.3%
2.9%
3.4%
4.2%
2.6%
3.7%

4
3.4%
2.4%
3.1%
3.4%
2.2%
3.1%

5
3.9%
2.8%
3.3%
3.2%
2.2%
3.2%

Table 3-40. Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails in
plans for RapidArc patients’ target structures
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Imaging Couch Top
Patient
Prostate Min Dose Loss (%)
Prostate Max Dose Loss (%)
Prostate Mean Dose Loss (%)
PTV Min Dose Loss (%)
PTV Max Dose Loss (%)
PTV Mean Dose Loss (%)

1
1.9%
1.7%
1.7%
1.9%
1.5%
1.7%

2
1.6%
2.6%
1.6%
2.3%
1.3%
1.7%

3
2.9%
2.6%
2.5%
2.8%
1.9%
2.6%

4
2.3%
1.8%
2.2%
2.6%
1.7%
2.2%

5
2.2%
1.8%
2.2%
2.3%
1.5%
2.1%

Table 3-41. Minimum, maximum, and mean prescription dose loss between the clinical scenario and imaging
couch top only plans for RapidArc patients’ target structures

Averages

Plan Type:
Average Prostate Min Dose Loss (%)
Average Prostate Max Dose Loss (%)
Average Prostate Mean Dose Loss (%)
Average PTV Min Dose Loss (%)
Average PTV Max Dose Loss (%)
Average PTV Mean Dose Loss (%)

Rails Out
3.5%
2.6%
3.2%
3.6%
2.3%
3.2%

Rails In
3.5%
2.5%
2.9%
3.3%
2.3%
3.1%

Imaging Couch
Top Only
2.2%
2.1%
2.0%
2.4%
1.6%
2.1%

Table 3-42. Average prescription dose loss between the clinical scenario and plans with rails out, rails in, and
imaging couch top only for RapidArc patients’ target structures

On average, the mean dose loss to the prostate and PTV was comparable for
RapidArc with the rails out and the rails in, typically around 3%. This is expected because
both the couch top and rails are traversed regardless of rail position with the arc field
arrangement as shown in Figure 2-4. On average, the majority of the dose loss is associated
with the imaging couch only, and less contribution is from the rails. This is unlike the IMRT
plans in which the rails contributed the most to dose loss. This is expected because the
couch top is continuously traversed through the posterior fields during RapidArc instead of
at only two beam positions as with the IMRT beam arrangement used.
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The dose losses to the targets for RapidArc were, on average, less than the losses
observed with the rails out for IMRT and more than the losses with the rails in for IMRT.
The dose loss due to the couch top alone was the same, on average, within 0.2% for
RapidArc and IMRT. The same order was not observed for coverage losses to the targets
for RapidArc and IMRT. All couch and rail configurations (rails out, rails in, and couch top
only) demonstrated greater loss in target coverage with RapidArc compared to IMRT.

3.6.3 Critical Structures: RapidArc
Similar to 3.4.3, the volume of normal tissue structures receiving doses that are
assessed during treatment planning were analyzed with the RapidArc plan DVH’s. The
dose-volume information for the clinical scenario plans is shown in Table 3-43. The dosevolume information for the rails out, rails in, and couch top only plans are shown in Table
3-44, Table 3-45, and Table 3-46, respectively. A summary of the average dose-volume
information across all patients and plans is shown in Table 3-47.

Rectum

Bladder

Clinical
Scenario
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
51%
45%
24%
13%
7%
0%
8%

Patient 2
38%
33%
20%
12%
7%
0%
19%

Patient 3
41%
32%
17%
10%
4%
0%
10%

Patient 4
44%
36%
20%
13%
6%
0%
12%

Patient 5
17%
15%
9%
6%
3%
0%
11%

Table 3-43. Dose-volume data for each RapidArc clinical scenario plan as a function of clinical DVH dosevolume constraints
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Rectum

Bladder

Rails Out
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
50%
43%
22%
11%
2%
0%
7%

Patient 2
37%
31%
18%
11%
1%
0%
17%

Patient 3
38%
29%
15%
7%
0%
0%
9%

Patient 4
41%
33%
18%
10%
0%
0%
11%

Patient 5
17%
14%
8%
5%
1%
0%
10%

Table 3-44. Dose-volume data for each RapidArc rails out plan as a function of clinical DVH dose-volume
constraints

Rectum

Bladder

Rails In
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
49%
42%
22%
11%
2%
0%
7%

Patient 2
36%
31%
18%
11%
2%
0%
17%

Patient 3
37%
29%
15%
7%
0%
0%
9%

Patient 4
41%
33%
18%
10%
0%
0%
11%

Patient 5
16%
14%
8%
5%
1%
0%
10%

Table 3-45. Dose-volume data for each RapidArc rails in plan as a function of clinical DVH dose-volume
constraints

Rectum

Bladder

Imaging Couch
Top
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Patient 1
50%
43%
23%
12%
5%
0%
7%

Patient 2
37%
32%
19%
11%
4%
0%
18%

Patient 3
38%
30%
16%
8%
1%
0%
10%

Patient 4
42%
34%
19%
11%
0%
0%
12%

Patient 5
17%
14%
9%
5%
2%
0%
10%

Table 3-46. Dose-volume data for each RapidArc imaging couch top only plan as a function of clinical DVH
dose-volume constraints
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Rectum

Bladder

Averages
40 Gy<60%
45 Gy<50%
60 Gy<40%
70 Gy<20%
75.6 Gy<15%
78-80 Gy <5%
70 Gy<20%

Clinical
Scenario
38%
32%
18%
11%
5%
0%
12%

Couch
with Rails
Out
36%
30%
16%
9%
1%
0%
11%

Couch
with Rails
In
36%
30%
16%
9%
1%
0%
11%

Imaging
Couch
Top Only
37%
31%
17%
9%
2%
0%
11%

Table 3-47. Average dose-volume data for all plan iterations as a function of clinical DVH dose-volume
constraints

On average, the rectum and bladder received less dose to their volumes when the
imaging couch top and/or rails were included in the plans. This indicates that when the
couch and rails are not included in treatment planning, the critical structures are receiving
less dose than indicated by the clinical scenario.
3.7 Tumor Control Probability: RapidArc
3.7.1 TCP Results: RapidArc
The DVH information from each RapidArc patient’s plans (clinical scenario, rails
out, and rails in) was used along with the specific input parameters mentioned in section
2.5.1 for the TCP model. Values for the imaging couch top only plan were not calculated as
this does not represent a clinically deliverable plan for RapidArc. The results are shown
below for all patients in 3-48 and averaged over all patients in 3-49.
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RapidArc
TCP

Clinical
Scenario

Rails
Out

Rails In

Patient 1
Patient 2
Patient 3
Patient 4

87%
87%
90%
87%

81%
82%
82%
78%

81%
82%
83%
79%

Patient 5

87%

79%

80%

3-48. RapidArc TCP results for each patient’s clinical scenario, rails out, and rails in plans

RapidArc TCP

Clinical
Scenario

Rails
Out

Rails
In

88%

81%

81%

3-49. RapidArc TCP results averaged over all patients

The RapidArc TCP results show a reduction in predicted tumor control due to the
attenuation of the couch top and rails not being accounted for in treatment planning. While
clinically it is believed that 88% of patient tumors would be controlled with the developed
treatment plans, in fact, because less dose is actually being delivered, only 81% of tumors
would be controlled. The TCP reduction for each patient’s rails out and rails in plan were
the same. This trend is consistent with the magnitudes of dose and volume loss shown in
3.6.1 and 3.6.2; specifically that both the rails out and rails in plans, on average, had similar
dose and volume coverage losses to the targets.
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Chapter 4 Discussion
4.1

General Discussion
4.1.1 Specific Aim 1
Our results for specific aim 1 looked at the relative attenuation of the imaging couch

top, mesh couch top, and rails of the Varian Exact Couch, as shown in the results in Chapter
3, section 1. They indicate three things: first, that the rails demonstrate a large amount of
beam attenuation when traversed, secondly, that there is a measurable contribution of the
imaging couch top to the attenuation, and thirdly, that the amount of attenuation has an
angular dependency. This aim was meant to establish that our couch components do cause
attenuation that could lead to dosimetric impact and to confirm that the magnitude of
attenuation was similar to that of other published results.
The results in Table 3-1 show that when the rails are in the out position, attenuation
occurs due to intersection with the couch top and rails from 115-135 degrees and,
symmetrically, from 225-245 degrees of gantry rotation with the greatest attenuation of the
beam at 120 and 240 regardless of which couch top was used. When the rails were in, the
angles of intersection were from 160 to 205 degrees excluding 180 degrees where there is a
gap between the two rails. The findings that these gantry angles are problematic for couchrail-beam intersection are consistent with the study by Wagner et al that found attenuation
for similar gantry angles on the Varian Exact Couch (20). The magnitude of this maximum
attenuation was larger than 20% when both the rails and imaging couch were traversed and
more than 17% when the rails and mesh tops were traversed in the out position. With the
rails in and the imaging couch top, the magnitude of the attenuation was as high as 14%.
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These results are reasonably consistent with the literature that found up to 17% attenuation
for a variety of couches and rails (12,13,14).
The 3% difference between the maximum attenuation of the imaging couch top and
mesh couch top with the rails out can attributed to the added attenuation that imaging couch
top has. The greater attenuating properities of the imaging couch versus the mesh couch top
are illustrated in the third column of Table 3-1 and range from 3 to 5% greater attenuation
by the imaging couch top alone. This result is higher than the findings by Wagner et al who
measured 1.49% - 3.20% attenuation of the imaging couch top (20). This difference could
be due to differences in material used for measurement; we used a 6-MV build up cap and
Wagner et al used a cylindrical PMMA phantom. Other explanations for the disagreement
could be due to differences in linac machine output, positioning of the ion chamber, and
measurement devices. The varying attenuation as a function of beam angle can be attributed
to possible heterogeneities in couch density, differing path lengths of material being
trasversed by different gantry angles, and systematic positional errors in the ion chamber.
An inconsistent difference between the mesh couch top and imaging couch top was shown
in the results at 115 and 245 degrees, where the mesh top attenuates more than the imaging
top [approximately 12% and 5%, respectively for both angles]. This could be attributed to
positional uncertainity in the ion chamber caused when it had to be moved and repositioned
after the mesh insert was added to the couch. Another possibility is that the result is correct
and due to the greater density of the mesh top on the edges than the rest of the couch top
whereas the imaging top is fairly uniform in composition and density.
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The angluar depedence on attenuation by the couch rails can be attributed to known
intentional heterogeneity in the cabon fiber rails as modeled in the Eclipse TPS in Figure
2-2. The carbon fiber rails are composed of a dense rectangular outer shell and a hollow
inner compartment. This non-uniform strucutre and density will cause differing attenuation
as a function of gantry angle as was observed and ranged from 3.5% to 17% for the
measurements with the mesh top. A larger magnitude of attenuation over the angles that
intersected with the rails and imaging top was observed, but the trend was the same as the
mesh top; the attenuation decreased and then increased as the rails were traversed which is
consistent with the non-uniformity of the rails. This trend is similar to the Wagner study that
found rail attenuation ranging from 8.83% to 17.01% for the Varian Exact Couch rails (20).
An interesting inconsistency is observed at the data point at 180 degrees with the
imaging couch top and rails in. At this location there is no relative attenuation measured,
which seems to be inconsistent with our conclusion that the imaging couch top itself causes
appreciable attenuation. However, this could be due to a partial intersection of the beam
with the rails that creates in-scatter from the rails into the middle of the couch, compensating
for the attenuation of the couch top.
In conclusion, for specific aim 1, we observed attenuation by the rails and imaging
couch top consistent, except for a higher measured attention by the mesh top, with published
results in the literature. The dosimetric impact of this attenuation is evaluated in specfic aims
2 and 3. The mesh couch top was not observed to appreciably attenuate the beam as
compared to the flat panel, imaging top and rails and will thus be explored only as an
additional investigation within the discussion.
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4.1.2 Specific Aim 2
Our results from the first part of specific aim 2, which evaluated the ability of the
Eclipse TPS to accurately predict the dose pertubation caused by the Varian Exact Couch
are shown in section 3.3.1 as percent differences between the measured absolute dose for a
delivered plan and the TPS calculated dose for the hybrid plan that included the couch and
rails in the same configuration as was delivered. For all plans, both IMRT and RapidArc,
and all rail configurations, we observed agreement of 0.7%. Although having better
agreement when the couch and rails were taken into account showed that the TPS
represented a better measure of treatment delivery reality, we also wanted to compare our
results to the results in the literature for similar studies.
In comparing our results to the three other studies that also evaluted the ability of
their respective treatment planning system to predict the attenuation through their couch
strucutures, we found similar agreement with our study. The study by Mihaylov et al found
argeement between computed and measured values of predicted dose for variety of set,
open field-sizes within 2% (11). The study by Myint et al found agreement within 2% as
well when the treatment couch was incorporated into the Theraplan Plus v3.8 TPS via a CT
image of the couch top (13). Finally, the study by Prooijen et al also found agreement
within 2% when CT images of their couches were incorporated into the Pinnacle TPS (14).
We believe that our results, an average agreement of 0.7% or less, are better than the other
results in the literature for two reasons: Our agreement is better (0.7% compared to 2%) and
for all except the Prooijen study, patient plans were not used for verification of their
respective couch models. Those other studies mentioned used static, open field beam
through the couch and/or rails (depending on the features of their respective couch model)
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into a phantom with an ion chamber. They then compared the predicted dose calculated in
their TPS for that beam to the measured value. The Prooijen study also verified the utlity of
their TPS with the same type of phantom measurements, but additionally used film
measurements with one 4-field IMRT plans with three posterior fields to verify the ability of
their TPS to account for the couch and rails. They found agreement within 2%, but as was
previously mentioned, their rail model did not reflect the non-uniform structure of one of
their couch rails and this measurment was only performed for one case. From this, we
concluded that the accurary of the Eclipse TPS to account for the couch and rails is better
than the other methods for couch modeling presented in the current literature.
One study was previously mentioned in the discussion evaluated the accuracy of the
Eclipse TPS couch models in addition to measuring the attenuating properties of the couch
and rails. A study by Wagner et al 2011 compared the accuracy of the couch parameters
included in the Eclipse TPS to measured values (20). They found that the default HU values
were in good agreement with the HU numbers they obtained from CT images for both the
imaging couch top filling (-1000 default vs -995 optimal) and rails (200 default vs 225
optimal). In contrast, the carbon plate’s HUs was set too high (-300 default vs -750 optimal).
However, even with this disagreement, the overall resultant disagreement between Eclipse
TPS calculated values of attenuation through the couch top and rails structures and measured
values were only 0.84% + 0.15% with a 6 MV photon beam (20). Although the
disagreement is large between measured and default HU values, the resulting disagreement
in measured dose is small and, furthermore, our agreement between predicted and measured
dose was, on average, better than the value reported by Wagner et al when we used the
default HU values.
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The results comparing our measurments to the clinical experience using the clinical
IMRT QA protocol at MDACC are shown in section 3.3.2. All plans had worse agreement
when the couch and rails were not taken into consideration using the TPS compared to our
results in section 3.3.1 that did account for the strucutures. The disagreement varied from
1.7% to 4.8% on average for the various configurations and delivery modalities. An
interesting point to highlight from this is that the MDACC passing criteria for absolute point
dose for a clinical plan must have agreement within +3%. This means that, on average, all
of the IMRT and RapidArc plans delivered with the rails out failed our clinical passing
criteria. However, as mentioned, treatments are commonly performed leaving the rails out
for this beam arrangmement. The dose disagreement error is not detected because during
IMRT QA, the rails are moved to avoid intersecting the beam, thereby avoiding these
failures. So, with our QA, we think the plans are passing with, on average, 1.7%
disagreement but are in fact being delivered in a configuration that is at 4.8% disagreement.
The potential impact of this error is addressed in the discussion along with recommendations
on how to fix it in the conclusions.
4.1.3 Specific Aim 3
Evaluation of our DVH data gathered for all plan iterations for each patient for target
coverage and dose showed that when the Varian Exact Couch with imaging insert and rails
are not accounted for in treatment planning, there is, on average, clinically unacceptable
losses of dose and coverage to target structures. For the IMRT deliveries, every plan with
the rails out failed our coverage criteria of 98% and 95% of prescription dose to the prostate
and PTV, respectively. There was a wide range of losses in coverage to both structures; for
example, as seen in Table 3-19, coverage to the prostate drops to only 3% coverage for one
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patient while it drops to just 80% for another. These differences can result from a variety of
factors: Each patient’s IMRT plans had different MU’s at each beam angle as shown in
Figure 3-7, the volume of each patient’s prostate and PTV varied as mentioned in the
appendix to this thesis, and the position of the patient on the modeled table also had some
variability. All of these factors can contribute the wide range of differences observed and
would be expected in a given population of patients. It should, therefore, be noted that the
magnitudes of the losses of coverage are not meant to be true for all patients clinically, but
rather, to highlight that often the effects of the couch and rails are unacceptable clinically.
There was less loss of coverage observed for the IMRT plans with the rails in than
with the rails out as shown in Table 3-20. This was expected based on our clinical beam
arrangement; our 8-field set-up only had two posterior fields at 225 and 135 degrees that
only intersected with the rails when they were out laterally. So, the coverage loss observed
with the rails in is completely attributable to the effect of the couch top. This was verified in
Table 3-21, which shows that the loss of coverage is the same for plans with the rails in and
plans that have the couch top only. As before, a wide variety of coverage losses were
observed; as low as 62% prostate coverage was observed, while two patients showed no
clinically significant loss of coverage for this configuration. This could be attributed to the
differences mentioned in the previous section between patient anatomy and patient plans.
However, it is important to note that on average the presence of the couch top resulted in
failure of planning criteria, although not to the same degree as with the rails in and, should,
therefore, not be considered a negligible contributor to attenuation with IMRT.
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An interesting discrepancy is seen for the target coverage losses for IMRT patients 1
and 4 as shown in Table 3-19 through Table 3-21for which these patients did not lose a
clinically significant amount of coverage with the rails in and imaging couch top only.
However, this discrepancy is not seen when looking at those patients’ loses of target dose in
Table 3-24 and Table 3-25; specifically that both patients lose an average amount of dose as
compared to the other patients. This seeming discrepancy is explained by looking at the
mean doses to these patients’ targets. Patients 1 and 4 had the highest mean doses to their
prostates (79 and 78 Gy, respectively) which allowed them to lose an average amount of
target dose without appreciably affecting their target coverage.
In summary, for the losses in coverage to target structures observed with IMRT plans
with varying couch and rail configurations, the rails contributed most to the loss in coverage
(when beams intercepted the rails), while the couch top caused less loss. While the couch
top at times (patients 1 and 4) did not cause a clinically unacceptable loss in coverage, on
average, a clinically unacceptable loss of coverage was observed.
The results for dose loss to the target structures with IMRT delivery followed the
same pattern: the rails caused the greatest loss of prescription dose on average (when
intercepted) while the couch top contributed less. On average, the mean loss of prescription
dose to the prostate was 4.2% with the rails out and 2% for both rails in and couch top only.
These would all be clinically unacceptable if they resulted in the mean dose to these targets
being below the prescription dose of 76Gy.
In comparing these results to the one study in the literature that evaluated dose and
target coverage loss for IMRT patients by Prooijen et al, it is difficult to draw comparisons.
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As previously mentioned, they retrospectively evaluated the impact of the couch and rails
for five IMRT patients that presented intersection problems through posterior fields at the
time of treatment. They found up to a 3% reduction in PTV coverage and 0.1% to 1.3% loss
of prescription dose, as defined by the 95% isodose line (14). We cannot compare these
results to ours for two reasons: the authors did not say which treatment couch, disease site,
prescription, or beam arrangements were used on the five patients evaluated so we cannot
assess if our results should be comparable, and secondly, they evaluated losses at the 95%
isodose line while we evaluated losses at the 100% isodose line.
The average losses in coverage to target structures with the RapidArc plans were
found to be more alarming than those observed for the IMRT plans. Table 3-38 shows that
the coverage for rails out and rails in is comparable at 18% and 17%, respectively. The
contribution from the couch top alone, on average, caused a drop to 40% coverage. This
illustrates that for RapidArc treatments, the imaging couch top contributes most to the loss
in target coverage, not the rails as with IMRT. This result makes sense because with our 2arc field arrangement, the couch top is intersected for more gantry angles and therefore more
MUs than the rails. Also, the loss in coverage being nearly identical with the rails in versus
the rails out makes because, unlike IMRT, the rails are traversed by our 2-arcs regardless of
their position. However, it should be noted that this trend was not observed in all patients.
This is mostly likely due to the differing doses and dose distributions between the IMRT and
RapidArc plans for the same patient.
The dose loss to the target structures for our RapidArc plans were less than the losses
observed for IMRT, but still could result in clinically unacceptable plans with approximately
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3% prescription dose loss with both rails out and rails in, with 2% from the couch top alone.
This means, unlike for IMRT, the imaging couch top contributed most to coverage and dose
loss to target structures. There are no studies published in the literature to-date investigating
the dosimetric impact due to Arc Therapy, which is a novel feature of this work.
The possible long-term impact of the target dose and coverage losses observed is
depicted by the average TCP reduction of 7.7%. The average loss of 7.7% in tumor control
indicates that of the patients treated, 7.7% would be predicted to have tumor recurrence
simply because the couch and rails were not taken into account during treatment planning.
However, there are many uncertainties to consider when using TCP models. Many of the
input parameters to the model (e.g., γ 50, TCD50, a) are dependent upon clinical data that are
related to patient outcome, which can cause variance in the TCP values. Also, there is the
further complication of life expectancy in typical prostate cancer patients, whose typical age
at diagnosis is 68 years and who have an average life expectancy of 78.5 years (1,21); this
factor may prevent manifestations of recurrences on the order predicted by the TCP
modeling.
The results from our novel investigation of the effect of the couch and rails on the
rectal and bladder critical structures highlight a possible problem with our current DVH
constraints. The values associated with dose tolerances to structural volumes are based on
long-term studies in late effect toxicity to patients. If, as is shown in Table 3-30 for IMRT
plans and Table 3-47 for RapidArc plans, patients with posterior treatments have been
having less of the volume of their normal tissue structures receiving high doses, then are the
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DVH constraints truly representing toxicity limits for patient populations? Answering this
would require much additional investigation but is an important clinical question to raise.
Another interesting point is evaluating how well the losses in dose to the targets
matched with the losses to the ion chamber measured during IMRT QA. The losses in dose
is, on average, consistent with the loss in dose measured with our IMRT QA protocol; on
average there was a 4.8% dose loss to the ion chamber using our IMRT QA protocol for a
plan with the rails out and an average of 4.2% dose loss to the prostate expected from our
DVH information. The largest difference between IMRT QA measurement and DVH
expectation was observed in one patient with a 6.2% dose loss to ion chamber and a 4.1%
loss to the prostate from DVH information. While our clinical IMRT QA protocol seems to
reasonably predict the loss of dose we observed with our DVH’s, such assessment provides
no information about the spatial distribution of the dose loss or coverage loss.
4.1.4 Follow-Up Study: Mesh Couch Top
The Varian Exact Couch comes with two couch top inserts: the solid carbon fiber
imaging insert used for linacs with on-board imagers (OBI) and the thin, transparent mesh
top insert used, typically, on non-OBI linacs. The reason for the difference in couch tops is
that the mesh design is visible in the KV-images taken with the OBI’s and so the imaging
insert is used because it has a uniform density structure that does not show up on film.
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Figure 4-1. Varian Exact Couch with mesh top insert

As both Varian Exact couch inserts are used clinically at MDACC, we decided to do
an additional investigation into the dosimetric impact of the mesh couch top by creating a
plan for each patient’s IMRT and RapidArc plans that included the unipanel mesh top only
and repeat specific aim 3. The results for the target coverage for the IMRT plans are shown
below and show that, with the exception of the PTV coverage on patient 3, the presence of
the mesh insert did not result in a clinical failure of coverage, unlike the imaging insert
shown next to our results for the mesh insert in Table 4-2. It is important to note that the
following tables compare only the impact of the couch top. The rails are additional
attenuation that would need to be considered when evaluating the overall impact of a
particular couch and rail configuration.
Mesh Couch Top
Patient
Prostate % Volume Coverage at Rx Dose
PTV % Volume Coverage at Rx Dose

1
100%
98%

2
100%
96%

3
100%
93%

4
100%
95%

5
100%
97%

Table 4-1. Coverage of target structures at prescription dose for IMRT with mesh couch top only
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IMRT Plans
Prostate % Volume Coverage at Rx Dose
PTV % Volume Coverage at Rx Dose

Mesh Couch Top
100%
96%

Imaging Couch Top
84%
79%

Table 4-2. Average coverage of targets at prescription dose for IMRT plans comparing both couch tops

Likewise, the loss of dose to target structures was less than with the imaging insert as
shown in Table 4-3. This average mean loss of 0.3% would likely not cause a failure in the
mean dose required to have tumor control unless the mean dose to the prostate was exactly
76 Gy when planned without the couch. This acceptable dose reduction would only apply if
the rails were not intersected by the beam. As shown in the results, the rails can have the
greatest impact for IMRT, and would cause plan failure if intersected regardless of couch
insert.

IMRT Plan:
Average Prostate Min Dose Loss (%)
Average Prostate Max Dose Loss (%)
Average Prostate Mean Dose Loss (%)
Average PTV Min Dose Loss (%)
Average PTV Max Dose Loss (%)
Average PTV Mean Dose Loss (%)

Mesh Couch
Top
0.4%
0.4%
0.3%
0.3%
0.4%
0.3%

Imaging Couch
Top
1.9%
1.8%
2.0%
1.5%
1.9%
1.9%

Table 4-3. Average percentage of minimum, maximum, and mean prescription dose loss from both couch tops

The results for the mesh top insert on our RapidArc plans are shown below in Tables
4-4 and Table 4-5. Although the mesh top did not cause a clinically significant loss of target
coverage to patient 2, the rest of the patient plans would not be acceptable even with the
mesh top. However, the loss is much less than with the imaging couch as shown in Table
4-5.
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Mesh Couch Top
Patient
Prostate % Volume Coverage at Rx Dose
PTV % Volume Coverage at Rx Dose

1
88%
93%

2
99%
98%

3
100%
91%

4
79%
85%

5
89%
93%

Table 4-4. Coverage of target structures at prescription dose for RapidArc with mesh couch top only

RapidArc Plans
Prostate % Volume Coverage at Rx Dose
PTV % Volume Coverage at Rx Dose

Mesh Couch Top
91%
92%

Imaging Couch Top
40%
57%

Table 4-5. Average coverage of targets at prescription dose for RapidArc plans for both couch tops

The dose loss caused by the mesh insert, as with IMRT, was less than the imaging
insert but still greater than the loss by the mesh insert in the IMRT plans. However, with an
average mean of 0.6% loss of prescription dose, it may not represent a clinically
unacceptable loss in dose. However, because the rails cannot be avoided in RapidArc, it
would not be possible to deliver with this little dose loss. It merely demonstrates that the
mesh top causes less of a loss than the imaging insert investigated throughout this thesis.
RapidArc Plans
Average Prostate Min Dose Loss (%)
Average Prostate Max Dose Loss (%)
Average Prostate Mean Dose Loss (%)
Average PTV Min Dose Loss (%)
Average PTV Max Dose Loss (%)
Average PTV Mean Dose Loss (%)

Mesh Insert
0.6%
0.6%
0.6%
0.6%
0.5%
0.6%

Imaging Insert
2.2%
2.1%
2.0%
2.4%
1.6%
2.1%

Table 4-6. Average percentage of minimum, maximum, and mean prescription dose loss from both couch tops
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Chapter 5 Conclusions
The attenuation of the posterior treatment fields for both IMRT and RapidArc plans by
the Varian Exact couch with imaging insert and support rails causes a clinically
unacceptable loss of dose and coverage to the target structures associated with prostate
cancer treatment if these support structures are not taken into account. The magnitude of the
loss of target coverage and dose is clinically significant to the extent that ignoring the couch
and rails structures resulted in plan failure, on average, for all IMRT and RapidArc couch
and rail positions. This is important as it represents a clinically unacceptable difference
between what dose and coverage we think a plan is will deliver to a patient and the reality of
what is being delivered.
To solve this discrepancy for IMRT plans, the rails should be moved during
treatment to avoid the attenuating the treatment beam. This could be done by noting what
gantry angles would intersect with the rails out and rails in and checking for intersections at
those angles during patient treatment. This would avoid the approximately 2% dose loss and
49% coverage loss to the prostate we observed. However, as was observed, the imaging
couch top itself contributes to unacceptable losses in some of our patient cases and since it is
not avoidable during treatment, it should be accounted for in the TPS either using a
validated couch model like the Eclipse TPS provides or increasing posterior MU’s by an
appropriate couch factor. For clinics that are especially high volume and/or cannot
implement such changes in planning protocol, using the mesh top couch in lieu of the
imaging couch top was shown in our discussion to result in acceptably small dose and
coverage loss assuming the rails are moved. If the rails were not moved and left in the out
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position with the mesh top, a dose loss of 2.4% and, most likely, a clinically unacceptable
coverage loss to the prostate.
Solving this discrepancy for RapidArc plans is more difficult since the rails cannot
be moved during treatment due to the continuous nature of treatment delivery. Moreover,
the imaging couch top contributed substantially to the dose loss. Also, as we showed in the
discussion, although the mesh top caused less loss of dose and coverage to target structures,
they were still clinically unacceptable. When taken together, the mesh top and rails should
cause approximately 1.6% dose loss to the prostate for either rail position. Therefore, both
the couch top (imaging and mesh) and rails need to be accounted for in treatment planning
to be consistent with what we clinically want to deliver to achieve effective tumor control.
Finally, for IMRT QA it is essential that the rail position used during QA is the same
as during treatment. Although some institutions may have a policy of moving the rails
during treatment, as noted, this is not a universal practice and IMRT QA is commonly done
to avoid the rails while this is not always done for treatment, resulting in large dose and
coverage losses. As shown, this would be most important to implement for IMRT plans but
there was also a slight difference observed in RapidArc with rail position and, therefore,
consistent placement of rails for QA and treatment should also be implemented.
We hypothesized that the presence of the Varian Exact imaging couch top and rails
would not demonstrate a clinical impact for IMRT and Arc Therapy. For this work, a
clinical impact was defined to be a change that would cause a failure of the plan based on
clinical planning criteria used in our clinic: 98% coverage of prescription dose to the
prostate, 95% to the PTV, meeting of normal tissue DVH constraints. Our results have
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shown our hypothesis to be false since the presence of the couch top and rails caused failure
of the clinical target dose and coverage planning criteria; this was manifest as a reduction in
TCP.
5.2

Future Work
Future work on this project should include consulting with the department of

radiation physics about the feasibility of implementing couch models in future treatment
planning. Other additional work should include a similar investigation on the effect on other
disease sites with different beam arrangements, investigation of the effect of other clinically
used couches, and further use of our DVH information to assess the predicted decrease in
tumor control probability (TCP) anticipated by the loss of dose to our target structures using
an appropriate biological model.
Finally, the most involved future endeavor should be a re-evaluation of our current
DVH constraints for normal tissue structures and how accurately they fit the late-term
effects they are meant to prevent given the discrepancies we noted between the doses
structures were believed to receive clinically and the doses they received in reality. This
could be done by retrospective analysis of the effect of the couch and rails on critical
structures for patients’ outcome data that was used to arrive at the current clinical DVH
constraints as well as a normal tissue complication probability (NTCP) modeling analysis of
our DVH results.
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Chapter 6 Appendix
6.1 IMRT Plans
A sampling of the data from all five patient IMRT plans is included in this appendix.
Patients representing a small, medium, and large prostate volume were chosen to for
inclusion in the appendix. Patient 1 with a prostate volume of 33 cm3 was determined to be
a small prostate volume in our sample of patients, Patient 3 with a prostate volume of 47
cm3 was determined to be a medium prostate volume in our sample of patients, and patient 4
with a volume of 74.5 cm3 was determined to be a large prostate volume in our sample of
patients.
6.1.1 IMRT DVH
The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively in Figure 6-1 through Figure 6-3 displayed below. Each clinical scenario plan,
which is the outer most pair of prostate and PTV lines in each plan passed MDACC’s
planning criteria of at least 98% coverage of the prostate and 95% coverage of the PTV by
the prescription dose of 76 Gy. The next pair of PTV and prostate DVH lines shifted to the
left, closest to the clinical scenario represents both the plans with the rails in and the imaging
couch top only for all patients. The inner most set of prostate and PTV DVH lines, the
greatest shift left from the clinical scenario represents the plan with the rails out in all the
patients.
The DVH’s for the three patients shown are consistent with the appearance of the
other DVH’s in terms of how the target DVH lines are shifted. The full DVH’s are shown
here and one can note a difference in the normal tissue dose-volumes (shown in yellow for
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the bladder and green for the rectum) which is due to differing planning constraints and
differing normal tissue volumes.

Figure 6-1. Relative volume vs absolute dose DVH for patient 1 (small prostate). The PTV, prostate, rectum,
and bladder are displayed in blue, red, green, and yellow, respectively

Figure 6-2. Relative volume vs absolute dose DVH for patient 3 (medium prostate). The PTV, prostate,
rectum, and bladder are displayed in blue, red, green, and yellow, respectively
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Figure 6-3. Relative volume vs absolute dose DVH for patient 4 (large Prostate). The PTV, prostate, rectum,
and bladder are displayed in blue, red, green, and yellow, respectively

6.1.2 IMRT Isodose Comparisons
The representative clinical scenario IMRT plan next to its subsequent iterations with
the rails out, rails in, and couch top only for the same CT slice are displayed below in Figure
6-4 though Figure 6-12. The clinical scenario on the left panel of each figure shows
complete coverage of the prostate (in blue colorwash) by the 76 Gy isodose line (in red),
indicating complete coverage of the structure on that CT slice when the couch and rails are
not included in the plan, as is clinical practice at MDACC. The image in the right panel
show the changes in the prescription isodose coverage of the target when the couch and rails
are considered.
The medium and large sized prostates show a pattern of the prescription isodose lines
breaking around the target consistent with the representative data presented in the thesis.
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The small prostate shown with patient 1, however, has a different pattern. There is no
visible breaking of the prescription isodose lines on the target. This could be attributed, as
was noted, that the patient had the fewest plan MU’s through the posterior field of any
patient and, most importantly, the highest mean dose to the prostate which could explain the
lack of coverage loss by the prescription isodose line.

Figure 6-4. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for patient 1 (small
prostate) with prostate shown in red colorwash

Figure 6-5. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for patient 1 (small
prostate) with prostate shown in red colorwash
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Figure 6-6. Clinical scenario IMRT plan (left panel) and imaging couch top only plan (right panel) for patient
1 (small prostate) with prostate shown in red colorwash

Figure 6-7. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for patient 3 (medium
prostate) with prostate shown in blue colorwash

Figure 6-8. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for patient 3 (medium
prostate) with prostate shown in blue colorwash

91

Figure 6-9. Clinical scenario IMRT plan (left panel) and imaging couch top only plan (right panel) for patient
3 (medium prostate) with prostate shown in blue colorwash

Figure 6-10. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for patient 4 (large
prostate) with prostate shown in blue colorwash

Figure 6-11. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for patient 4 (large
prostate) with prostate shown in blue colorwash
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Figure 6-12. Clinical scenario IMRT plan (left panel) and imaging couch top only (right panel) for patient 4
(large prostate) with prostate shown in blue colorwash

6.1.3 IMRT Plan Subtractions
The IMRT plan subtractions show areas of dose loss between the clinical scenario
and plans that including the patient support structures. Figure 6-13 through Figure 6-21
represent the spatial areas and magnitudes of dose loss between the clinical scenario and the
plans that account for various components and configurations of the couch and rails.
The spatial patterns of dose loss along the posterior fields are consistent for all the
patients shown. The only differences are in magnitude of dose losses which were previously
addressed for each patient.
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Figure 6-13. Clinical scenario IMRT Plan subtracted from rails out plan for patient 1 (small prostate) with
prostate shown in blue colorwash

Figure 6-14. Clinical scenario IMRT Plan subtracted from rails in plan for patient 1 (small prostate) with
prostate shown in blue colorwash
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Figure 6-15. Clinical scenario IMRT Plan subtracted from imaging couch top only plan for patient 1 (small
prostate) with prostate shown in blue colorwash

Figure 6-16. Clinical scenario IMRT plan subtracted from rails out plan for patient 3 (medium prostate) with
prostate shown in blue colorwash
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Figure 6-17. Clinical scenario IMRT plan subtracted from rails in plan for patient 3 (medium prostate) with
prostate shown in blue colorwash

Figure 6-18. Clinical scenario IMRT plan subtracted from imaging couch top only plan for patient 3 (medium
prostate) with prostate shown in blue colorwash
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Figure 6-19. Clinical scenario IMRT plan subtracted from rails out plan for patient 4 (large prostate) with
prostate shown in blue colorwash

Figure 6-20. Clinical scenario IMRT plan subtracted from rails in plan for patient 4 (large prostate) with
prostate shown in blue colorwash

97

Figure 6-21. Clinical scenario IMRT plan subtracted from imaging couch top only plan for patient 4 (large
prostate) with prostate shown in blue colorwash

6.2 RapidArc Plans
A sampling of the data from all five patient RapidArc plans is included in this appendix.
Since the same planning CT images were used for the IMRT and RapidArc plans, the same
representative patients (patients 1, 3, and 4) are shown in this section representing small,
medium, and large prostate volumes from our study population.
6.2.1 RapidArc DVH
The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow,
respectively in Figure 6-22 through Figure 6-24. Each clinical scenario plan which is the
outer most pair of prostate and PTV lines in each plan passed MDACC’s planning criteria of
at least 98% coverage of the prostate and 95% coverage of the PTV by the prescription dose
of 76 Gy. The next pair of PTV and prostate DVH lines shifted to the left, closest to the
clinical scenario represents the imaging couch top only for all patients and indicates that the
98

couch top itself contributes to coverage loss to target structures. The inner most two sets of
prostate and PTV DVH lines, the greatest shift left from the clinical scenario, represent the
plan with the rails out and rails in for all the patients. The rails out and rails in target DVH
lines are very close and sometimes overlapping. This is reasonable because, as the beam
arrangement shows in Figure 2-4 in section 2.2.2, both the couch top and rails are
intersected during delivery. Coverage to the target structures is lost when either the imaging
couch top or rails are intersected.
The pattern of DVH target line shifts for all patients is consistent with respect to the
order noted in the section above. The magnitudes of the coverage losses vary and are not
easily quantifiable using these figures and were addressed quantitatively in section 3.3.4.
Also, the normal tissue dose-volumes varies greatly between patients and is due to differing
absolute volumes, anatomy location, and dose constraints used for planning. However, all
clinical DVH criteria were met for the normal tissue structures.

Figure 6-22. Relative volume vs absolute dose RapidArc DVH for patient 1 (small prostate). The PTV,
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively
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Figure 6-23. Relative volume vs absolute dose RapidArc DVH for patient 3 (medium prostate). The PTV,
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively

Figure 6-24. Relative volume vs absolute dose RapidArc DVH for patient 4 (large prostate). The PTV,
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively
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6.2.2 RapidArc Isodsose Comparisons
The representative clinical scenario RapidArc plan next to its subsequent iterations
with the rails out, rails in, and couch top only for the same CT slice are displayed below in
Figure 6-25 through Figure 6-33. The clinical scenario on the left panel of each figure shows
complete coverage of the prostate (in blue colorwash) by the 76 Gy isodose line (in red),
indicating complete coverage of the structure on that CT slice when the couch and rails are
not included in the plan, as is clinical practice at MDACC. The image in the right panel
show the changes in the prescription isodose coverage of the target when the couch and rails
are considered.
Unlike the IMRT isodose figures shown, RapidArc isodose comparisons show a loss
in isodose coverage of the target for each patient that is consistent with the mean patient data
shown in the thesis.

Figure 6-25. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for patient 1 (small
prostate) with prostate shown in blue colorwash
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Figure 6-26. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for patient 1 (small
prostate) with prostate shown in blue colorwash

Figure 6-27. Clinical scenario RapicPlan (left panel) and imaging couch top only (right panel) for patient 1
(small prostate) with prostate shown in blue colorwash
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Figure 6-28. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for patient 3 (medium
prostate) with prostate shown in blue colorwash

Figure 6-29. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for patient 3 (medium
prostate) with prostate shown in blue colorwash

Figure 6-30. Clinical scenario RapicPlan (left panel) and imaging couch top only plan (right panel) for patient
3 (medium prostate) with prostate shown in blue colorwash

103

Figure 6-31. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for patient 4 (large
prostate) with prostate shown in blue colorwash

Figure 6-32. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for patient 4 (large prostate)
with prostate shown in blue colorwash
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Figure 6-33. Clinical scenario RapicPlan (left panel) and imaging couch top only plan (right panel) for patient
4 (large prostate) with prostate shown in blue colorwash

6.2.3 RapidArc Plan Subtractions
The RapidArc plan subtractions show areas of dose loss between the clinical
scenario and plans that including the patient support structures. Figure 6-34through Figure
6-42 show the spatial areas and magnitudes of dose loss between the clinical scenario and
the plans that account for various components and configurations of the couch and rails.
The plan subtractions shown for each patient are consistent in the pattern of dose
loss; specifically the loss is along the position of the rails. The magnitude of dose loss
varies and was addressed in the thesis. These variances, as noted, can be due to the amount
of MU’s going through the posterior arcs.

Figure 6-34. Clinical scenario RapidArc Plan subtracted from rails out plan for patient 1 (small prostate) with
prostate shown in blue colorwash
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Figure 6-35. Clinical scenario RapidArc Plan subtracted from rails in plan for patient 1 (small prostate) with
prostate shown in blue colorwash

Figure 6-36. Clinical scenario RapidArc Plan subtracted from imaging couch top only plan for patient 1
(small prostate) with prostate shown in blue colorwash
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Figure 6-37. Clinical scenario RapidArc plan subtracted from rails out plan for patient 3 (mean prostate) with
prostate shown in blue colorwash

Figure 6-38. Clinical scenario RapidArc plan subtracted from rails in plan for patient 3 (mean prostate) with
prostate shown in blue colorwash
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Figure 6-39. Clinical scenario RapidArc plan subtracted from imaging couch top only plan for patient 3
(mean prostate) with prostate shown in blue colorwash

Figure 6-40. Clinical scenario RapidArc plan subtracted from rails out plan for patient 4 (large prostate) with
prostate shown in blue colorwash
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Figure 6-41. Clinical scenario RapidArc plan subtracted from rails in plan for patient 4 (large prostate) with
prostate shown in blue colorwash

Figure 6-42. Clinical scenario RapidArc plan subtracted from imaging couch top only plan for patient 4 (large
prostate) with prostate shown in blue colorwash
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